id	sid	tid	token	lemma	pos
dti-1401	1	1	https://doi.org/10.1177/1177392818785136	https://doi.org/10.1177/1177392818785136	PROPN
dti-1401	1	2	drug	drug	NOUN
dti-1401	1	3	target	target	NOUN
dti-1401	1	4	insights	insight	NOUN
dti-1401	1	5	volume	volume	VERB
dti-1401	1	6	12	12	NUM
dti-1401	1	7	:	:	PUNCT
dti-1401	1	8	1–2	1–2	NUM
dti-1401	1	9	©	©	ADP
dti-1401	1	10	the	the	DET
dti-1401	1	11	author(s	author(s	NOUN
dti-1401	1	12	)	)	PUNCT
dti-1401	1	13	2018	2018	NUM
dti-1401	1	14	reprints	reprint	NOUN
dti-1401	1	15	and	and	CCONJ
dti-1401	1	16	permissions	permission	NOUN
dti-1401	1	17	:	:	PUNCT
dti-1401	2	1	sagepub.co.uk/journalspermissions.nav	sagepub.co.uk/journalspermissions.nav	PROPN
dti-1401	2	2	doi	doi	PROPN
dti-1401	2	3	:	:	PUNCT
dti-1401	2	4	10.1177/1177392818785136	10.1177/1177392818785136	NUM
dti-1401	2	5	creative	creative	ADJ
dti-1401	2	6	commons	common	NOUN
dti-1401	2	7	non	non	ADJ
dti-1401	2	8	commercial	commercial	PROPN
dti-1401	2	9	cc	cc	PROPN
dti-1401	2	10	by	by	ADP
dti-1401	2	11	-	-	PUNCT
dti-1401	2	12	nc	nc	PROPN
dti-1401	2	13	:	:	PUNCT
dti-1401	2	14	this	this	DET
dti-1401	2	15	article	article	NOUN
dti-1401	2	16	is	be	AUX
dti-1401	2	17	distributed	distribute	VERB
dti-1401	2	18	under	under	ADP
dti-1401	2	19	the	the	DET
dti-1401	2	20	terms	term	NOUN
dti-1401	2	21	of	of	ADP
dti-1401	2	22	the	the	DET
dti-1401	2	23	creative	creative	ADJ
dti-1401	2	24	commons	common	NOUN
dti-1401	2	25	attribution	attribution	NOUN
dti-1401	2	26	-	-	PUNCT
dti-1401	2	27	noncommercial	noncommercial	ADJ
dti-1401	2	28	4.0	4.0	NUM
dti-1401	2	29	license	license	NOUN
dti-1401	2	30	(	(	PUNCT
dti-1401	2	31	http://www.creativecommons.org/licenses/by-nc/4.0/	http://www.creativecommons.org/licenses/by-nc/4.0/	PROPN
dti-1401	2	32	)	)	PUNCT
dti-1401	2	33	which	which	PRON
dti-1401	2	34	permits	permit	VERB
dti-1401	2	35	non	non	ADJ
dti-1401	2	36	-	-	ADJ
dti-1401	2	37	commercial	commercial	ADJ
dti-1401	2	38	use	use	NOUN
dti-1401	2	39	,	,	PUNCT
dti-1401	2	40	reproduction	reproduction	NOUN
dti-1401	2	41	and	and	CCONJ
dti-1401	2	42	distribution	distribution	NOUN
dti-1401	2	43	of	of	ADP
dti-1401	2	44	the	the	DET
dti-1401	2	45	work	work	NOUN
dti-1401	2	46	without	without	ADP
dti-1401	2	47	further	further	ADJ
dti-1401	2	48	permission	permission	NOUN
dti-1401	2	49	provided	provide	VERB
dti-1401	2	50	the	the	DET
dti-1401	2	51	original	original	ADJ
dti-1401	2	52	work	work	NOUN
dti-1401	2	53	is	be	AUX
dti-1401	2	54	attributed	attribute	VERB
dti-1401	2	55	as	as	ADP
dti-1401	2	56	specified	specify	VERB
dti-1401	2	57	on	on	ADP
dti-1401	2	58	the	the	DET
dti-1401	2	59	sage	sage	NOUN
dti-1401	2	60	and	and	CCONJ
dti-1401	2	61	open	open	ADJ
dti-1401	2	62	access	access	NOUN
dti-1401	2	63	pages	page	NOUN
dti-1401	2	64	(	(	PUNCT
dti-1401	2	65	https://us.sagepub.com/en-us/nam/open-access-at-sage	https://us.sagepub.com/en-us/nam/open-access-at-sage	NOUN
dti-1401	2	66	)	)	PUNCT
dti-1401	2	67	.	.	PUNCT
dti-1401	3	1	during	during	ADP
dti-1401	3	2	the	the	DET
dti-1401	3	3	drug	drug	NOUN
dti-1401	3	4	review	review	NOUN
dti-1401	3	5	process	process	NOUN
dti-1401	3	6	,	,	PUNCT
dti-1401	3	7	as	as	SCONJ
dti-1401	3	8	noted	note	VERB
dti-1401	3	9	in	in	ADP
dti-1401	3	10	the	the	DET
dti-1401	3	11	center	center	NOUN
dti-1401	3	12	for	for	ADP
dti-1401	3	13	drug	drug	NOUN
dti-1401	3	14	evaluation	evaluation	NOUN
dti-1401	3	15	and	and	CCONJ
dti-1401	3	16	research	research	NOUN
dti-1401	3	17	(	(	PUNCT
dti-1401	3	18	cder	cder	NOUN
dti-1401	3	19	,	,	PUNCT
dti-1401	3	20	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm	NOUN
dti-1401	3	21	)	)	PUNCT
dti-1401	3	22	,	,	PUNCT
dti-1401	3	23	one	one	NUM
dti-1401	3	24	of	of	ADP
dti-1401	3	25	the	the	DET
dti-1401	3	26	reviewers	reviewer	NOUN
dti-1401	3	27	found	find	VERB
dti-1401	3	28	that	that	SCONJ
dti-1401	3	29	the	the	DET
dti-1401	3	30	drug	drug	NOUN
dti-1401	3	31	caused	cause	VERB
dti-1401	3	32	microglial	microglial	ADJ
dti-1401	3	33	aggregates	aggregate	NOUN
dti-1401	3	34	throughout	throughout	ADP
dti-1401	3	35	the	the	DET
dti-1401	3	36	brain	brain	NOUN
dti-1401	3	37	and	and	CCONJ
dti-1401	3	38	spinal	spinal	ADJ
dti-1401	3	39	cord	cord	NOUN
dti-1401	3	40	of	of	ADP
dti-1401	3	41	study	study	NOUN
dti-1401	3	42	animals	animal	NOUN
dti-1401	3	43	(	(	PUNCT
dti-1401	3	44	cynomolgus	cynomolgus	ADJ
dti-1401	3	45	monkeys	monkey	NOUN
dti-1401	3	46	)	)	PUNCT
dti-1401	3	47	,	,	PUNCT
dti-1401	3	48	albeit	albeit	SCONJ
dti-1401	3	49	a	a	DET
dti-1401	3	50	nonclinical	nonclinical	ADJ
dti-1401	3	51	finding	finding	NOUN
dti-1401	3	52	,	,	PUNCT
dti-1401	3	53	and	and	CCONJ
dti-1401	3	54	recommended	recommend	VERB
dti-1401	3	55	nonapproval	nonapproval	ADJ
dti-1401	3	56	for	for	ADP
dti-1401	3	57	clinical	clinical	ADJ
dti-1401	3	58	use	use	NOUN
dti-1401	3	59	.	.	PUNCT
dti-1401	4	1	while	while	SCONJ
dti-1401	4	2	the	the	DET
dti-1401	4	3	biological	biological	ADJ
dti-1401	4	4	significance	significance	NOUN
dti-1401	4	5	of	of	ADP
dti-1401	4	6	this	this	DET
dti-1401	4	7	finding	finding	NOUN
dti-1401	4	8	,	,	PUNCT
dti-1401	4	9	particularly	particularly	ADV
dti-1401	4	10	as	as	SCONJ
dti-1401	4	11	it	it	PRON
dti-1401	4	12	relates	relate	VERB
dti-1401	4	13	to	to	ADP
dti-1401	4	14	the	the	DET
dti-1401	4	15	dosing	dosing	NOUN
dti-1401	4	16	(	(	PUNCT
dti-1401	4	17	7	7	NUM
dti-1401	4	18	-	-	ADJ
dti-1401	4	19	fold	fold	ADJ
dti-1401	4	20	safety	safety	NOUN
dti-1401	4	21	margin	margin	NOUN
dti-1401	4	22	at	at	ADP
dti-1401	4	23	the	the	DET
dti-1401	4	24	150	150	NUM
dti-1401	4	25	-	-	PUNCT
dti-1401	4	26	mg	mg	NUM
dti-1401	4	27	dose	dose	PROPN
dti-1401	4	28	)	)	PUNCT
dti-1401	4	29	,	,	PUNCT
dti-1401	4	30	at	at	ADP
dti-1401	4	31	which	which	PRON
dti-1401	4	32	the	the	DET
dti-1401	4	33	drug	drug	NOUN
dti-1401	4	34	was	be	AUX
dti-1401	4	35	studied	study	VERB
dti-1401	4	36	remains	remain	VERB
dti-1401	4	37	unclear	unclear	ADJ
dti-1401	4	38	,	,	PUNCT
dti-1401	4	39	it	it	PRON
dti-1401	4	40	must	must	AUX
dti-1401	4	41	be	be	AUX
dti-1401	4	42	noted	note	VERB
dti-1401	4	43	that	that	SCONJ
dti-1401	4	44	microglial	microglial	ADJ
dti-1401	4	45	aggregates	aggregate	NOUN
dti-1401	4	46	did	do	AUX
dti-1401	4	47	not	not	PART
dti-1401	4	48	cause	cause	VERB
dti-1401	4	49	neuronal	neuronal	ADJ
dti-1401	4	50	degeneration	degeneration	NOUN
dti-1401	4	51	,	,	PUNCT
dti-1401	4	52	axonal	axonal	ADJ
dti-1401	4	53	fragmentation	fragmentation	NOUN
dti-1401	4	54	,	,	PUNCT
dti-1401	4	55	or	or	CCONJ
dti-1401	4	56	demyelination	demyelination	NOUN
dti-1401	4	57	.	.	PUNCT
dti-1401	5	1	the	the	DET
dti-1401	5	2	drug	drug	NOUN
dti-1401	5	3	was	be	AUX
dti-1401	5	4	subsequently	subsequently	ADV
dti-1401	5	5	approved	approve	VERB
dti-1401	5	6	.	.	PUNCT
dti-1401	6	1	the	the	DET
dti-1401	6	2	black	black	ADJ
dti-1401	6	3	-	-	PUNCT
dti-1401	6	4	box	box	NOUN
dti-1401	6	5	warning	warning	NOUN
dti-1401	6	6	for	for	ADP
dti-1401	6	7	zinbryta	zinbryta	NOUN
dti-1401	6	8	package	package	NOUN
dti-1401	6	9	insert	insert	NOUN
dti-1401	6	10	did	do	AUX
dti-1401	6	11	note	note	VERB
dti-1401	6	12	that	that	SCONJ
dti-1401	6	13	,	,	PUNCT
dti-1401	6	14	across	across	ADP
dti-1401	6	15	all	all	DET
dti-1401	6	16	clinical	clinical	ADJ
dti-1401	6	17	trials	trial	NOUN
dti-1401	6	18	,	,	PUNCT
dti-1401	6	19	serious	serious	ADJ
dti-1401	6	20	drug	drug	NOUN
dti-1401	6	21	-	-	PUNCT
dti-1401	6	22	related	relate	VERB
dti-1401	6	23	hepatic	hepatic	ADJ
dti-1401	6	24	injury	injury	NOUN
dti-1401	6	25	occurred	occur	VERB
dti-1401	6	26	in	in	ADP
dti-1401	6	27	1.7	1.7	NUM
dti-1401	6	28	%	%	NOUN
dti-1401	6	29	of	of	ADP
dti-1401	6	30	zinbryta	zinbryta	NOUN
dti-1401	6	31	-	-	PUNCT
dti-1401	6	32	treated	treat	VERB
dti-1401	6	33	patients	patient	NOUN
dti-1401	6	34	.	.	PUNCT
dti-1401	7	1	furthermore	furthermore	ADV
dti-1401	7	2	,	,	PUNCT
dti-1401	7	3	5	5	NUM
dti-1401	7	4	%	%	NOUN
dti-1401	7	5	of	of	ADP
dti-1401	7	6	patients	patient	NOUN
dti-1401	7	7	on	on	ADP
dti-1401	7	8	zinbryta	zinbryta	NOUN
dti-1401	7	9	developed	develop	VERB
dti-1401	7	10	serious	serious	ADJ
dti-1401	7	11	immune	immune	NOUN
dti-1401	7	12	-	-	PUNCT
dti-1401	7	13	mediated	mediate	VERB
dti-1401	7	14	disorders	disorder	NOUN
dti-1401	7	15	including	include	VERB
dti-1401	7	16	skin	skin	NOUN
dti-1401	7	17	reactions	reaction	NOUN
dti-1401	7	18	and	and	CCONJ
dti-1401	7	19	lymphadenopathy	lymphadenopathy	ADJ
dti-1401	7	20	.	.	PUNCT
dti-1401	8	1	across	across	ADP
dti-1401	8	2	all	all	DET
dti-1401	8	3	clinical	clinical	ADJ
dti-1401	8	4	studies	study	NOUN
dti-1401	8	5	,	,	PUNCT
dti-1401	8	6	immune	immune	NOUN
dti-1401	8	7	-	-	PUNCT
dti-1401	8	8	mediated	mediate	VERB
dti-1401	8	9	disorders	disorder	NOUN
dti-1401	8	10	occurred	occur	VERB
dti-1401	8	11	in	in	ADP
dti-1401	8	12	28	28	NUM
dti-1401	8	13	%	%	NOUN
dti-1401	8	14	of	of	ADP
dti-1401	8	15	patients	patient	NOUN
dti-1401	8	16	on	on	ADP
dti-1401	8	17	zinbryta	zinbryta	NOUN
dti-1401	8	18	,	,	PUNCT
dti-1401	8	19	including	include	VERB
dti-1401	8	20	skin	skin	NOUN
dti-1401	8	21	reactions	reaction	NOUN
dti-1401	8	22	and	and	CCONJ
dti-1401	8	23	lymphadenopathy	lymphadenopathy	ADJ
dti-1401	8	24	.	.	PUNCT
dti-1401	9	1	some	some	DET
dti-1401	9	2	patients	patient	NOUN
dti-1401	9	3	required	require	VERB
dti-1401	9	4	invasive	invasive	ADJ
dti-1401	9	5	procedures	procedure	NOUN
dti-1401	9	6	for	for	ADP
dti-1401	9	7	diagnosis	diagnosis	NOUN
dti-1401	9	8	and	and	CCONJ
dti-1401	9	9	some	some	DET
dti-1401	9	10	patients	patient	NOUN
dti-1401	9	11	did	do	AUX
dti-1401	9	12	not	not	PART
dti-1401	9	13	improve	improve	VERB
dti-1401	9	14	even	even	ADV
dti-1401	9	15	after	after	ADP
dti-1401	9	16	stopping	stop	VERB
dti-1401	9	17	zinbryta	zinbryta	NOUN
dti-1401	9	18	.	.	PUNCT
dti-1401	10	1	curiously	curiously	ADV
dti-1401	10	2	,	,	PUNCT
dti-1401	10	3	no	no	DET
dti-1401	10	4	cases	case	NOUN
dti-1401	10	5	of	of	ADP
dti-1401	10	6	inflammatory	inflammatory	ADJ
dti-1401	10	7	encephalitis	encephalitis	NOUN
dti-1401	10	8	or	or	CCONJ
dti-1401	10	9	meningoencephalitis	meningoencephalitis	NOUN
dti-1401	10	10	were	be	AUX
dti-1401	10	11	noted	note	VERB
dti-1401	10	12	,	,	PUNCT
dti-1401	10	13	however	however	ADV
dti-1401	10	14	,	,	PUNCT
dti-1401	10	15	but	but	CCONJ
dti-1401	10	16	a	a	DET
dti-1401	10	17	safety	safety	NOUN
dti-1401	10	18	and	and	CCONJ
dti-1401	10	19	tolerability	tolerability	NOUN
dti-1401	10	20	study	study	NOUN
dti-1401	10	21	did	do	AUX
dti-1401	10	22	mention	mention	VERB
dti-1401	10	23	drug	drug	NOUN
dti-1401	10	24	reaction	reaction	NOUN
dti-1401	10	25	with	with	ADP
dti-1401	10	26	eosinophilia	eosinophilia	PROPN
dti-1401	10	27	and	and	CCONJ
dti-1401	10	28	systemic	systemic	ADJ
dti-1401	10	29	symptoms	symptom	NOUN
dti-1401	10	30	or	or	CCONJ
dti-1401	10	31	dress	dress	NOUN
dti-1401	10	32	syndrome	syndrome	NOUN
dti-1401	10	33	as	as	ADP
dti-1401	10	34	a	a	DET
dti-1401	10	35	complication.1	complication.1	PROPN
dti-1401	10	36	however	however	ADV
dti-1401	10	37	,	,	PUNCT
dti-1401	10	38	dress	dress	NOUN
dti-1401	10	39	syndrome	syndrome	NOUN
dti-1401	10	40	which	which	PRON
dti-1401	10	41	is	be	AUX
dti-1401	10	42	a	a	DET
dti-1401	10	43	purely	purely	ADV
dti-1401	10	44	clinical	clinical	ADJ
dti-1401	10	45	event	event	NOUN
dti-1401	10	46	will	will	AUX
dti-1401	10	47	only	only	ADV
dti-1401	10	48	be	be	AUX
dti-1401	10	49	recognized	recognize	VERB
dti-1401	10	50	if	if	SCONJ
dti-1401	10	51	clinicians	clinician	NOUN
dti-1401	10	52	are	be	AUX
dti-1401	10	53	alert	alert	ADJ
dti-1401	10	54	to	to	ADP
dti-1401	10	55	the	the	DET
dti-1401	10	56	possibility	possibility	NOUN
dti-1401	10	57	and	and	CCONJ
dti-1401	10	58	are	be	AUX
dti-1401	10	59	trained	train	VERB
dti-1401	10	60	to	to	PART
dti-1401	10	61	recognize	recognize	VERB
dti-1401	10	62	such	such	ADJ
dti-1401	10	63	events	event	NOUN
dti-1401	10	64	and	and	CCONJ
dti-1401	10	65	not	not	PART
dti-1401	10	66	relegate	relegate	VERB
dti-1401	10	67	them	they	PRON
dti-1401	10	68	to	to	ADP
dti-1401	10	69	an	an	DET
dti-1401	10	70	“	"	PUNCT
dti-1401	10	71	ms	ms	NOUN
dti-1401	10	72	relapse	relapse	NOUN
dti-1401	10	73	.	.	PUNCT
dti-1401	10	74	”	"	PUNCT
dti-1401	11	1	as	as	SCONJ
dti-1401	11	2	there	there	PRON
dti-1401	11	3	is	be	VERB
dti-1401	11	4	no	no	DET
dti-1401	11	5	established	establish	VERB
dti-1401	11	6	method	method	NOUN
dti-1401	11	7	to	to	PART
dti-1401	11	8	revisit	revisit	VERB
dti-1401	11	9	data	datum	NOUN
dti-1401	11	10	sets	set	NOUN
dti-1401	11	11	from	from	ADP
dti-1401	11	12	clinical	clinical	ADJ
dti-1401	11	13	trials	trial	NOUN
dti-1401	11	14	unless	unless	SCONJ
dti-1401	11	15	drug	drug	NOUN
dti-1401	11	16	companies	company	NOUN
dti-1401	11	17	themselves	themselves	PRON
dti-1401	11	18	put	put	VERB
dti-1401	11	19	out	out	ADP
dti-1401	11	20	such	such	ADJ
dti-1401	11	21	information	information	NOUN
dti-1401	11	22	in	in	ADP
dti-1401	11	23	the	the	DET
dti-1401	11	24	face	face	NOUN
dti-1401	11	25	of	of	ADP
dti-1401	11	26	drug	drug	NOUN
dti-1401	11	27	being	be	AUX
dti-1401	11	28	pulled	pull	VERB
dti-1401	11	29	from	from	ADP
dti-1401	11	30	the	the	DET
dti-1401	11	31	market	market	NOUN
dti-1401	11	32	,	,	PUNCT
dti-1401	11	33	that	that	DET
dti-1401	11	34	particular	particular	ADJ
dti-1401	11	35	piece	piece	NOUN
dti-1401	11	36	of	of	ADP
dti-1401	11	37	information	information	NOUN
dti-1401	11	38	will	will	AUX
dti-1401	11	39	forever	forever	ADV
dti-1401	11	40	be	be	AUX
dti-1401	11	41	lost	lose	VERB
dti-1401	11	42	.	.	PUNCT
dti-1401	12	1	the	the	DET
dti-1401	12	2	ema	ema	PROPN
dti-1401	12	3	document	document	NOUN
dti-1401	12	4	published	publish	VERB
dti-1401	12	5	on	on	ADP
dti-1401	12	6	march	march	PROPN
dti-1401	12	7	6	6	NUM
dti-1401	12	8	,	,	PUNCT
dti-1401	12	9	2018	2018	NUM
dti-1401	12	10	,	,	PUNCT
dti-1401	12	11	notes	note	VERB
dti-1401	12	12	that	that	SCONJ
dti-1401	12	13	4	4	NUM
dti-1401	12	14	patients	patient	NOUN
dti-1401	12	15	developed	develop	VERB
dti-1401	12	16	skin	skin	NOUN
dti-1401	12	17	rash	rash	NOUN
dti-1401	12	18	and	and	CCONJ
dti-1401	12	19	involvement	involvement	NOUN
dti-1401	12	20	of	of	ADP
dti-1401	12	21	other	other	ADJ
dti-1401	12	22	organs	organ	NOUN
dti-1401	12	23	including	include	VERB
dti-1401	12	24	eosinophilia	eosinophilia	PROPN
dti-1401	12	25	,	,	PUNCT
dti-1401	12	26	whereas	whereas	SCONJ
dti-1401	12	27	5	5	NUM
dti-1401	12	28	other	other	ADJ
dti-1401	12	29	patients	patient	NOUN
dti-1401	12	30	developed	develop	VERB
dti-1401	12	31	multi	multi	ADJ
dti-1401	12	32	-	-	ADJ
dti-1401	12	33	organ	organ	ADJ
dti-1401	12	34	failure	failure	NOUN
dti-1401	12	35	probably	probably	ADV
dti-1401	12	36	related	relate	VERB
dti-1401	12	37	to	to	ADP
dti-1401	12	38	immune	immune	NOUN
dti-1401	12	39	-	-	PUNCT
dti-1401	12	40	mediated	mediate	VERB
dti-1401	12	41	phenomena	phenomenon	NOUN
dti-1401	12	42	.	.	PUNCT
dti-1401	13	1	specifically	specifically	ADV
dti-1401	13	2	,	,	PUNCT
dti-1401	13	3	none	none	NOUN
dti-1401	13	4	of	of	ADP
dti-1401	13	5	these	these	DET
dti-1401	13	6	cases	case	NOUN
dti-1401	13	7	were	be	AUX
dti-1401	13	8	initially	initially	ADV
dti-1401	13	9	identified	identify	VERB
dti-1401	13	10	as	as	ADP
dti-1401	13	11	secondary	secondary	ADJ
dti-1401	13	12	to	to	ADP
dti-1401	13	13	side	side	ADJ
dti-1401	13	14	effects	effect	NOUN
dti-1401	13	15	of	of	ADP
dti-1401	13	16	the	the	DET
dti-1401	13	17	drug	drug	NOUN
dti-1401	13	18	;	;	PUNCT
dti-1401	13	19	later	later	ADV
dti-1401	13	20	,	,	PUNCT
dti-1401	13	21	they	they	PRON
dti-1401	13	22	were	be	AUX
dti-1401	13	23	recognized	recognize	VERB
dti-1401	13	24	as	as	ADP
dti-1401	13	25	(	(	PUNCT
dti-1401	13	26	dress	dress	NOUN
dti-1401	13	27	)	)	PUNCT
dti-1401	13	28	a	a	DET
dti-1401	13	29	conclusion	conclusion	NOUN
dti-1401	13	30	that	that	PRON
dti-1401	13	31	could	could	AUX
dti-1401	13	32	have	have	VERB
dti-1401	13	33	major	major	ADJ
dti-1401	13	34	ramifications	ramification	NOUN
dti-1401	13	35	on	on	ADP
dti-1401	13	36	safety	safety	NOUN
dti-1401	13	37	,	,	PUNCT
dti-1401	13	38	and	and	CCONJ
dti-1401	13	39	how	how	SCONJ
dti-1401	13	40	data	datum	NOUN
dti-1401	13	41	are	be	AUX
dti-1401	13	42	interpreted	interpret	VERB
dti-1401	13	43	by	by	ADP
dti-1401	13	44	clinicians	clinician	NOUN
dti-1401	13	45	both	both	CCONJ
dti-1401	13	46	in	in	ADP
dti-1401	13	47	the	the	DET
dti-1401	13	48	clinical	clinical	ADJ
dti-1401	13	49	trials	trial	NOUN
dti-1401	13	50	and	and	CCONJ
dti-1401	13	51	developmental	developmental	ADJ
dti-1401	13	52	stages	stage	NOUN
dti-1401	13	53	of	of	ADP
dti-1401	13	54	the	the	DET
dti-1401	13	55	drug	drug	NOUN
dti-1401	13	56	as	as	ADV
dti-1401	13	57	well	well	ADV
dti-1401	13	58	as	as	ADP
dti-1401	13	59	in	in	ADP
dti-1401	13	60	phase	phase	NOUN
dti-1401	13	61	4	4	NUM
dti-1401	13	62	use	use	NOUN
dti-1401	13	63	of	of	ADP
dti-1401	13	64	the	the	DET
dti-1401	13	65	drug	drug	NOUN
dti-1401	13	66	after	after	ADP
dti-1401	13	67	approval	approval	NOUN
dti-1401	13	68	.	.	PUNCT
dti-1401	14	1	it	it	PRON
dti-1401	14	2	is	be	AUX
dti-1401	14	3	equally	equally	ADV
dti-1401	14	4	strange	strange	ADJ
dti-1401	14	5	that	that	SCONJ
dti-1401	14	6	no	no	DET
dti-1401	14	7	cases	case	NOUN
dti-1401	14	8	of	of	ADP
dti-1401	14	9	encephalitis	encephalitis	NOUN
dti-1401	14	10	or	or	CCONJ
dti-1401	14	11	meningoencephalitis	meningoencephalitis	NOUN
dti-1401	14	12	were	be	AUX
dti-1401	14	13	noted	note	VERB
dti-1401	14	14	in	in	ADP
dti-1401	14	15	the	the	DET
dti-1401	14	16	clinical	clinical	ADJ
dti-1401	14	17	trials	trial	NOUN
dti-1401	14	18	and	and	CCONJ
dti-1401	14	19	whether	whether	SCONJ
dti-1401	14	20	signs	sign	NOUN
dti-1401	14	21	and	and	CCONJ
dti-1401	14	22	symptoms	symptom	NOUN
dti-1401	14	23	were	be	AUX
dti-1401	14	24	erroneously	erroneously	ADV
dti-1401	14	25	missed	miss	VERB
dti-1401	14	26	or	or	CCONJ
dti-1401	14	27	misclassified	misclassifie	VERB
dti-1401	14	28	as	as	ADP
dti-1401	14	29	clinical	clinical	ADJ
dti-1401	14	30	worsening	worsening	NOUN
dti-1401	14	31	of	of	ADP
dti-1401	14	32	ms	ms	PROPN
dti-1401	14	33	remains	remain	VERB
dti-1401	14	34	a	a	DET
dti-1401	14	35	worry	worry	NOUN
dti-1401	14	36	.	.	PUNCT
dti-1401	15	1	if	if	SCONJ
dti-1401	15	2	this	this	PRON
dti-1401	15	3	is	be	AUX
dti-1401	15	4	the	the	DET
dti-1401	15	5	case	case	NOUN
dti-1401	15	6	,	,	PUNCT
dti-1401	15	7	the	the	DET
dti-1401	15	8	signs	sign	NOUN
dti-1401	15	9	are	be	AUX
dti-1401	15	10	ominous	ominous	ADJ
dti-1401	15	11	for	for	ADP
dti-1401	15	12	future	future	ADJ
dti-1401	15	13	drug	drug	NOUN
dti-1401	15	14	development	development	NOUN
dti-1401	15	15	strategies	strategy	NOUN
dti-1401	15	16	.	.	PUNCT
dti-1401	16	1	in	in	ADP
dti-1401	16	2	general	general	ADJ
dti-1401	16	3	,	,	PUNCT
dti-1401	16	4	the	the	DET
dti-1401	16	5	phenomenon	phenomenon	NOUN
dti-1401	16	6	of	of	ADP
dti-1401	16	7	“	"	PUNCT
dti-1401	16	8	ms	ms	PROPN
dti-1401	16	9	relapse	relapse	NOUN
dti-1401	16	10	”	"	PUNCT
dti-1401	16	11	remains	remain	VERB
dti-1401	16	12	a	a	DET
dti-1401	16	13	major	major	ADJ
dti-1401	16	14	concern	concern	NOUN
dti-1401	16	15	even	even	ADV
dti-1401	16	16	in	in	ADP
dti-1401	16	17	routine	routine	ADJ
dti-1401	16	18	clinical	clinical	ADJ
dti-1401	16	19	assessment	assessment	NOUN
dti-1401	16	20	of	of	ADP
dti-1401	16	21	patients	patient	NOUN
dti-1401	16	22	with	with	ADP
dti-1401	16	23	ms	ms	NOUN
dti-1401	16	24	on	on	ADP
dti-1401	16	25	medications	medication	NOUN
dti-1401	16	26	.	.	PUNCT
dti-1401	17	1	patients	patient	NOUN
dti-1401	17	2	are	be	AUX
dti-1401	17	3	unlikely	unlikely	ADJ
dti-1401	17	4	to	to	PART
dti-1401	17	5	be	be	AUX
dti-1401	17	6	told	tell	VERB
dti-1401	17	7	that	that	SCONJ
dti-1401	17	8	their	their	PRON
dti-1401	17	9	findings	finding	NOUN
dti-1401	17	10	are	be	AUX
dti-1401	17	11	“	"	PUNCT
dti-1401	17	12	drug	drug	NOUN
dti-1401	17	13	related	relate	VERB
dti-1401	17	14	”	"	PUNCT
dti-1401	17	15	and	and	CCONJ
dti-1401	17	16	more	more	ADV
dti-1401	17	17	likely	likely	ADV
dti-1401	17	18	told	tell	VERB
dti-1401	17	19	that	that	SCONJ
dti-1401	17	20	their	their	PRON
dti-1401	17	21	disease	disease	NOUN
dti-1401	17	22	is	be	AUX
dti-1401	17	23	worsening	worsen	VERB
dti-1401	17	24	.	.	PUNCT
dti-1401	18	1	it	it	PRON
dti-1401	18	2	is	be	AUX
dti-1401	18	3	important	important	ADJ
dti-1401	18	4	to	to	PART
dti-1401	18	5	note	note	VERB
dti-1401	18	6	that	that	SCONJ
dti-1401	18	7	almost	almost	ADV
dti-1401	18	8	all	all	DET
dti-1401	18	9	the	the	DET
dti-1401	18	10	cases	case	NOUN
dti-1401	18	11	described	describe	VERB
dti-1401	18	12	by	by	ADP
dti-1401	18	13	the	the	DET
dti-1401	18	14	ema	ema	PROPN
dti-1401	18	15	led	lead	VERB
dti-1401	18	16	to	to	ADP
dti-1401	18	17	pulling	pull	VERB
dti-1401	18	18	zinbryta	zinbryta	NOUN
dti-1401	18	19	off	off	ADP
dti-1401	18	20	the	the	DET
dti-1401	18	21	market	market	NOUN
dti-1401	18	22	,	,	PUNCT
dti-1401	18	23	and	and	CCONJ
dti-1401	18	24	the	the	DET
dti-1401	18	25	initial	initial	ADJ
dti-1401	18	26	assessment	assessment	NOUN
dti-1401	18	27	was	be	AUX
dti-1401	18	28	largely	largely	ADV
dti-1401	18	29	attributed	attribute	VERB
dti-1401	18	30	to	to	ADP
dti-1401	18	31	“	"	PUNCT
dti-1401	18	32	worsening	worsen	VERB
dti-1401	18	33	ms	ms	NOUN
dti-1401	18	34	disease	disease	NOUN
dti-1401	18	35	.	.	PUNCT
dti-1401	18	36	”	"	PUNCT
dti-1401	19	1	the	the	DET
dti-1401	19	2	mishap	mishap	NOUN
dti-1401	19	3	with	with	ADP
dti-1401	19	4	zinbryta	zinbryta	NOUN
dti-1401	19	5	ought	ought	AUX
dti-1401	19	6	to	to	PART
dti-1401	19	7	be	be	AUX
dti-1401	19	8	a	a	DET
dti-1401	19	9	warning	warning	NOUN
dti-1401	19	10	call	call	NOUN
dti-1401	19	11	to	to	ADP
dti-1401	19	12	all	all	DET
dti-1401	19	13	clinicians	clinician	NOUN
dti-1401	19	14	to	to	PART
dti-1401	19	15	revisit	revisit	VERB
dti-1401	19	16	definitions	definition	NOUN
dti-1401	19	17	of	of	ADP
dti-1401	19	18	what	what	PRON
dti-1401	19	19	represents	represent	VERB
dti-1401	19	20	an	an	DET
dti-1401	19	21	ms	ms	NOUN
dti-1401	19	22	relapse	relapse	NOUN
dti-1401	19	23	or	or	CCONJ
dti-1401	19	24	clinical	clinical	ADJ
dti-1401	19	25	worsening	worsening	NOUN
dti-1401	19	26	and	and	CCONJ
dti-1401	19	27	when	when	SCONJ
dti-1401	19	28	to	to	PART
dti-1401	19	29	seek	seek	VERB
dti-1401	19	30	alternative	alternative	ADJ
dti-1401	19	31	explanations	explanation	NOUN
dti-1401	19	32	for	for	ADP
dti-1401	19	33	“	"	PUNCT
dti-1401	19	34	ms	ms	PROPN
dti-1401	19	35	relapse	relapse	NOUN
dti-1401	19	36	.	.	PUNCT
dti-1401	19	37	”	"	PUNCT
dti-1401	20	1	dress	dress	NOUN
dti-1401	20	2	syndrome	syndrome	NOUN
dti-1401	20	3	and	and	CCONJ
dti-1401	20	4	daclizumab	daclizumab	NOUN
dti-1401	20	5	failure	failure	NOUN
dti-1401	20	6	—	—	PUNCT
dti-1401	20	7	were	be	AUX
dti-1401	20	8	potentially	potentially	ADV
dti-1401	20	9	dangerous	dangerous	ADJ
dti-1401	20	10	signs	sign	NOUN
dti-1401	20	11	missed	miss	VERB
dti-1401	20	12	in	in	ADP
dti-1401	20	13	clinical	clinical	ADJ
dti-1401	20	14	trials	trial	NOUN
dti-1401	20	15	?	?	PUNCT
dti-1401	21	1	jagannadha	jagannadha	PROPN
dti-1401	21	2	avasarala1,2	avasarala1,2	PROPN
dti-1401	21	3	1department	1department	NUM
dti-1401	21	4	of	of	ADP
dti-1401	21	5	internal	internal	ADJ
dti-1401	21	6	medicine	medicine	NOUN
dti-1401	21	7	/	/	SYM
dti-1401	21	8	division	division	NOUN
dti-1401	21	9	of	of	ADP
dti-1401	21	10	neurology	neurology	NOUN
dti-1401	21	11	,	,	PUNCT
dti-1401	21	12	school	school	NOUN
dti-1401	21	13	of	of	ADP
dti-1401	21	14	medicine	medicine	NOUN
dti-1401	21	15	,	,	PUNCT
dti-1401	21	16	university	university	NOUN
dti-1401	21	17	of	of	ADP
dti-1401	21	18	south	south	PROPN
dti-1401	21	19	carolina	carolina	PROPN
dti-1401	21	20	,	,	PUNCT
dti-1401	21	21	greenville	greenville	PROPN
dti-1401	21	22	,	,	PUNCT
dti-1401	21	23	sc	sc	PROPN
dti-1401	21	24	,	,	PUNCT
dti-1401	21	25	usa	usa	PROPN
dti-1401	21	26	.	.	PROPN
dti-1401	21	27	2greenville	2greenville	NUM
dti-1401	21	28	health	health	NOUN
dti-1401	21	29	system	system	NOUN
dti-1401	21	30	,	,	PUNCT
dti-1401	21	31	greenville	greenville	PROPN
dti-1401	21	32	,	,	PUNCT
dti-1401	21	33	sc	sc	PROPN
dti-1401	21	34	,	,	PUNCT
dti-1401	21	35	usa	usa	PROPN
dti-1401	21	36	abstract	abstract	PROPN
dti-1401	21	37	:	:	PUNCT
dti-1401	21	38	the	the	DET
dti-1401	21	39	us	us	PROPN
dti-1401	21	40	food	food	NOUN
dti-1401	21	41	and	and	CCONJ
dti-1401	21	42	drug	drug	PROPN
dti-1401	21	43	administration	administration	PROPN
dti-1401	21	44	(	(	PUNCT
dti-1401	21	45	fda	fda	PROPN
dti-1401	21	46	)	)	PUNCT
dti-1401	21	47	approved	approve	VERB
dti-1401	21	48	zinbryta	zinbryta	NOUN
dti-1401	21	49	,	,	PUNCT
dti-1401	21	50	an	an	DET
dti-1401	21	51	interleukin-2	interleukin-2	NUM
dti-1401	21	52	receptor	receptor	NOUN
dti-1401	21	53	blocking	block	VERB
dti-1401	21	54	antibody	antibody	NOUN
dti-1401	21	55	(	(	PUNCT
dti-1401	21	56	daclizumab	daclizumab	NOUN
dti-1401	21	57	;	;	PUNCT
dti-1401	21	58	biogen	biogen	PROPN
dti-1401	21	59	and	and	CCONJ
dti-1401	21	60	abbvie	abbvie	PROPN
dti-1401	21	61	)	)	PUNCT
dti-1401	21	62	for	for	ADP
dti-1401	21	63	the	the	DET
dti-1401	21	64	treatment	treatment	NOUN
dti-1401	21	65	of	of	ADP
dti-1401	21	66	adults	adult	NOUN
dti-1401	21	67	with	with	ADP
dti-1401	21	68	relapsing	relapse	VERB
dti-1401	21	69	forms	form	NOUN
dti-1401	21	70	of	of	ADP
dti-1401	21	71	multiple	multiple	ADJ
dti-1401	21	72	sclerosis	sclerosis	NOUN
dti-1401	21	73	(	(	PUNCT
dti-1401	21	74	ms	ms	NOUN
dti-1401	21	75	)	)	PUNCT
dti-1401	21	76	in	in	ADP
dti-1401	21	77	may	may	PROPN
dti-1401	21	78	,	,	PUNCT
dti-1401	21	79	2016	2016	NUM
dti-1401	21	80	.	.	PUNCT
dti-1401	22	1	it	it	PRON
dti-1401	22	2	was	be	AUX
dti-1401	22	3	also	also	ADV
dti-1401	22	4	approved	approve	VERB
dti-1401	22	5	by	by	ADP
dti-1401	22	6	the	the	DET
dti-1401	22	7	european	european	PROPN
dti-1401	22	8	union	union	PROPN
dti-1401	22	9	in	in	ADP
dti-1401	22	10	july	july	PROPN
dti-1401	22	11	,	,	PUNCT
dti-1401	22	12	2016	2016	NUM
dti-1401	22	13	.	.	PUNCT
dti-1401	23	1	zinbryta	zinbryta	NOUN
dti-1401	23	2	is	be	AUX
dti-1401	23	3	a	a	DET
dti-1401	23	4	long	long	ADV
dti-1401	23	5	-	-	PUNCT
dti-1401	23	6	acting	act	VERB
dti-1401	23	7	,	,	PUNCT
dti-1401	23	8	self	self	NOUN
dti-1401	23	9	-	-	PUNCT
dti-1401	23	10	administered	administer	VERB
dti-1401	23	11	monthly	monthly	ADJ
dti-1401	23	12	injection	injection	NOUN
dti-1401	23	13	that	that	PRON
dti-1401	23	14	was	be	AUX
dti-1401	23	15	branded	brand	VERB
dti-1401	23	16	as	as	ADP
dti-1401	23	17	a	a	DET
dti-1401	23	18	new	new	ADJ
dti-1401	23	19	ms	ms	NOUN
dti-1401	23	20	drug	drug	NOUN
dti-1401	23	21	for	for	ADP
dti-1401	23	22	patients	patient	NOUN
dti-1401	23	23	who	who	PRON
dti-1401	23	24	needed	need	VERB
dti-1401	23	25	a	a	DET
dti-1401	23	26	“	"	PUNCT
dti-1401	23	27	new	new	ADJ
dti-1401	23	28	option	option	NOUN
dti-1401	23	29	for	for	ADP
dti-1401	23	30	treatment	treatment	NOUN
dti-1401	23	31	.	.	PUNCT
dti-1401	23	32	”	"	PUNCT
dti-1401	24	1	it	it	PRON
dti-1401	24	2	blocks	block	VERB
dti-1401	24	3	interleukin-2	interleukin-2	NUM
dti-1401	24	4	receptor	receptor	NOUN
dti-1401	24	5	alpha	alpha	NOUN
dti-1401	24	6	(	(	PUNCT
dti-1401	24	7	cd25	cd25	PROPN
dti-1401	24	8	)	)	PUNCT
dti-1401	24	9	and	and	CCONJ
dti-1401	24	10	modulates	modulate	VERB
dti-1401	24	11	t	t	NOUN
dti-1401	24	12	-	-	PUNCT
dti-1401	24	13	cell	cell	NOUN
dti-1401	24	14	expansion	expansion	NOUN
dti-1401	24	15	.	.	PUNCT
dti-1401	25	1	the	the	DET
dti-1401	25	2	drug	drug	NOUN
dti-1401	25	3	was	be	AUX
dti-1401	25	4	withdrawn	withdraw	VERB
dti-1401	25	5	from	from	ADP
dti-1401	25	6	the	the	DET
dti-1401	25	7	market	market	NOUN
dti-1401	25	8	in	in	ADP
dti-1401	25	9	march	march	PROPN
dti-1401	25	10	,	,	PUNCT
dti-1401	25	11	2018	2018	NUM
dti-1401	25	12	following	follow	VERB
dti-1401	25	13	12	12	NUM
dti-1401	25	14	reports	report	NOUN
dti-1401	25	15	from	from	ADP
dti-1401	25	16	germany	germany	PROPN
dti-1401	25	17	(	(	PUNCT
dti-1401	25	18	9	9	NUM
dti-1401	25	19	)	)	PUNCT
dti-1401	25	20	,	,	PUNCT
dti-1401	25	21	united	united	PROPN
dti-1401	25	22	states	states	PROPN
dti-1401	25	23	(	(	PUNCT
dti-1401	25	24	2	2	NUM
dti-1401	25	25	)	)	PUNCT
dti-1401	25	26	,	,	PUNCT
dti-1401	25	27	and	and	CCONJ
dti-1401	25	28	spain	spain	PROPN
dti-1401	25	29	(	(	PUNCT
dti-1401	25	30	1	1	X
dti-1401	25	31	)	)	PUNCT
dti-1401	25	32	following	follow	VERB
dti-1401	25	33	the	the	DET
dti-1401	25	34	development	development	NOUN
dti-1401	25	35	of	of	ADP
dti-1401	25	36	“	"	PUNCT
dti-1401	25	37	inflammatory	inflammatory	ADJ
dti-1401	25	38	encephalitis	encephalitis	NOUN
dti-1401	25	39	and	and	CCONJ
dti-1401	25	40	meningoencephalitis	meningoencephalitis	NOUN
dti-1401	25	41	”	"	PUNCT
dti-1401	25	42	in	in	ADP
dti-1401	25	43	patients	patient	NOUN
dti-1401	25	44	on	on	ADP
dti-1401	25	45	zinbryta	zinbryta	NOUN
dti-1401	25	46	.	.	PUNCT
dti-1401	26	1	although	although	SCONJ
dti-1401	26	2	cases	case	NOUN
dti-1401	26	3	of	of	ADP
dti-1401	26	4	hepatotoxicity	hepatotoxicity	NOUN
dti-1401	26	5	made	make	VERB
dti-1401	26	6	news	news	NOUN
dti-1401	26	7	with	with	ADP
dti-1401	26	8	zinbryta	zinbryta	NOUN
dti-1401	26	9	earlier	early	ADV
dti-1401	26	10	along	along	ADP
dti-1401	26	11	this	this	DET
dti-1401	26	12	drug	drug	NOUN
dti-1401	26	13	’s	’s	ADV
dti-1401	26	14	postmarketing	postmarkete	VERB
dti-1401	26	15	journey	journey	NOUN
dti-1401	26	16	in	in	ADP
dti-1401	26	17	the	the	DET
dti-1401	26	18	treatment	treatment	NOUN
dti-1401	26	19	of	of	ADP
dti-1401	26	20	patients	patient	NOUN
dti-1401	26	21	with	with	ADP
dti-1401	26	22	ms	ms	PROPN
dti-1401	26	23	,	,	PUNCT
dti-1401	26	24	the	the	DET
dti-1401	26	25	european	european	PROPN
dti-1401	26	26	medicines	medicines	PROPN
dti-1401	26	27	agency	agency	NOUN
dti-1401	26	28	(	(	PUNCT
dti-1401	26	29	ema	ema	PROPN
dti-1401	26	30	)	)	PUNCT
dti-1401	26	31	ordered	order	VERB
dti-1401	26	32	a	a	DET
dti-1401	26	33	review	review	NOUN
dti-1401	26	34	of	of	ADP
dti-1401	26	35	the	the	DET
dti-1401	26	36	risks	risk	NOUN
dti-1401	26	37	of	of	ADP
dti-1401	26	38	hepatotoxicity	hepatotoxicity	NOUN
dti-1401	26	39	with	with	ADP
dti-1401	26	40	zinbryta	zinbryta	NOUN
dti-1401	26	41	use	use	PROPN
dti-1401	26	42	june	june	PROPN
dti-1401	26	43	,	,	PUNCT
dti-1401	26	44	2017	2017	NUM
dti-1401	26	45	;	;	PUNCT
dti-1401	26	46	this	this	DET
dti-1401	26	47	analysis	analysis	NOUN
dti-1401	26	48	will	will	AUX
dti-1401	26	49	focus	focus	VERB
dti-1401	26	50	on	on	ADP
dti-1401	26	51	the	the	DET
dti-1401	26	52	pharmacovigilance	pharmacovigilance	NOUN
dti-1401	26	53	data	datum	NOUN
dti-1401	26	54	concerning	concern	VERB
dti-1401	26	55	the	the	DET
dti-1401	26	56	central	central	ADJ
dti-1401	26	57	nervous	nervous	ADJ
dti-1401	26	58	system	system	NOUN
dti-1401	26	59	(	(	PUNCT
dti-1401	26	60	cns	cns	NOUN
dti-1401	26	61	)	)	PUNCT
dti-1401	26	62	complications	complication	NOUN
dti-1401	26	63	.	.	PUNCT
dti-1401	27	1	the	the	DET
dti-1401	27	2	details	detail	NOUN
dti-1401	27	3	of	of	ADP
dti-1401	27	4	the	the	DET
dti-1401	27	5	cns	cns	PROPN
dti-1401	27	6	complications	complication	NOUN
dti-1401	27	7	have	have	AUX
dti-1401	27	8	been	be	AUX
dti-1401	27	9	elucidated	elucidate	VERB
dti-1401	27	10	by	by	ADP
dti-1401	27	11	ema	ema	PROPN
dti-1401	27	12	.	.	PUNCT
dti-1401	28	1	every	every	DET
dti-1401	28	2	drug	drug	NOUN
dti-1401	28	3	failure	failure	NOUN
dti-1401	28	4	provides	provide	VERB
dti-1401	28	5	an	an	DET
dti-1401	28	6	opportunity	opportunity	NOUN
dti-1401	28	7	for	for	ADP
dti-1401	28	8	learning	learning	NOUN
dti-1401	28	9	,	,	PUNCT
dti-1401	28	10	but	but	CCONJ
dti-1401	28	11	it	it	PRON
dti-1401	28	12	is	be	AUX
dti-1401	28	13	also	also	ADV
dti-1401	28	14	noteworthy	noteworthy	ADJ
dti-1401	28	15	that	that	SCONJ
dti-1401	28	16	no	no	DET
dti-1401	28	17	fda	fda	PROPN
dti-1401	28	18	-	-	PUNCT
dti-1401	28	19	approved	approve	VERB
dti-1401	28	20	ms	ms	NOUN
dti-1401	28	21	drug	drug	NOUN
dti-1401	28	22	in	in	ADP
dti-1401	28	23	modern	modern	ADJ
dti-1401	28	24	times	time	NOUN
dti-1401	28	25	has	have	AUX
dti-1401	28	26	met	meet	VERB
dti-1401	28	27	with	with	ADP
dti-1401	28	28	such	such	DET
dti-1401	28	29	an	an	DET
dti-1401	28	30	untimely	untimely	ADJ
dti-1401	28	31	,	,	PUNCT
dti-1401	28	32	sudden	sudden	ADJ
dti-1401	28	33	,	,	PUNCT
dti-1401	28	34	and	and	CCONJ
dti-1401	28	35	inglorious	inglorious	ADJ
dti-1401	28	36	exit	exit	NOUN
dti-1401	28	37	.	.	PUNCT
dti-1401	29	1	this	this	PRON
dti-1401	29	2	should	should	AUX
dti-1401	29	3	serve	serve	VERB
dti-1401	29	4	as	as	ADP
dti-1401	29	5	a	a	DET
dti-1401	29	6	cautionary	cautionary	ADJ
dti-1401	29	7	tale	tale	NOUN
dti-1401	29	8	for	for	ADP
dti-1401	29	9	all	all	DET
dti-1401	29	10	clinicians	clinician	NOUN
dti-1401	29	11	who	who	PRON
dti-1401	29	12	use	use	VERB
dti-1401	29	13	“	"	PUNCT
dti-1401	29	14	newer	new	ADJ
dti-1401	29	15	ms	ms	NOUN
dti-1401	29	16	drugs	drug	NOUN
dti-1401	29	17	”	"	PUNCT
dti-1401	29	18	that	that	PRON
dti-1401	29	19	have	have	AUX
dti-1401	29	20	mushroomed	mushroom	VERB
dti-1401	29	21	in	in	ADP
dti-1401	29	22	recent	recent	ADJ
dti-1401	29	23	memory	memory	NOUN
dti-1401	29	24	following	follow	VERB
dti-1401	29	25	a	a	DET
dti-1401	29	26	flurry	flurry	NOUN
dti-1401	29	27	of	of	ADP
dti-1401	29	28	recent	recent	ADJ
dti-1401	29	29	fda	fda	PROPN
dti-1401	29	30	approvals	approval	NOUN
dti-1401	29	31	.	.	PUNCT
dti-1401	30	1	keywords	keyword	NOUN
dti-1401	30	2	:	:	PUNCT
dti-1401	30	3	daclizumab	daclizumab	NOUN
dti-1401	30	4	,	,	PUNCT
dti-1401	30	5	dress	dress	NOUN
dti-1401	30	6	syndrome	syndrome	NOUN
dti-1401	30	7	,	,	PUNCT
dti-1401	30	8	encephalitis	encephalitis	NOUN
dti-1401	30	9	,	,	PUNCT
dti-1401	30	10	meningoencephalitis	meningoencephalitis	NOUN
dti-1401	30	11	,	,	PUNCT
dti-1401	30	12	cns	cns	NOUN
dti-1401	30	13	toxicity	toxicity	NOUN
dti-1401	30	14	,	,	PUNCT
dti-1401	30	15	drug	drug	NOUN
dti-1401	30	16	trials	trial	NOUN
dti-1401	30	17	received	receive	VERB
dti-1401	30	18	:	:	PUNCT
dti-1401	30	19	march	march	PROPN
dti-1401	30	20	27	27	NUM
dti-1401	30	21	,	,	PUNCT
dti-1401	30	22	2018	2018	NUM
dti-1401	30	23	.	.	PUNCT
dti-1401	31	1	accepted	accept	VERB
dti-1401	31	2	:	:	PUNCT
dti-1401	31	3	june	june	PROPN
dti-1401	31	4	4	4	NUM
dti-1401	31	5	,	,	PUNCT
dti-1401	31	6	2018	2018	NUM
dti-1401	31	7	.	.	PUNCT
dti-1401	32	1	type	type	NOUN
dti-1401	32	2	:	:	PUNCT
dti-1401	32	3	perspective	perspective	PROPN
dti-1401	32	4	funding	funding	NOUN
dti-1401	32	5	:	:	PUNCT
dti-1401	32	6	the	the	DET
dti-1401	32	7	author(s	author(s	PROPN
dti-1401	32	8	)	)	PUNCT
dti-1401	32	9	received	receive	VERB
dti-1401	32	10	no	no	DET
dti-1401	32	11	financial	financial	ADJ
dti-1401	32	12	support	support	NOUN
dti-1401	32	13	for	for	ADP
dti-1401	32	14	the	the	DET
dti-1401	32	15	research	research	NOUN
dti-1401	32	16	,	,	PUNCT
dti-1401	32	17	authorship	authorship	NOUN
dti-1401	32	18	,	,	PUNCT
dti-1401	32	19	and/or	and/or	CCONJ
dti-1401	32	20	publication	publication	NOUN
dti-1401	32	21	of	of	ADP
dti-1401	32	22	this	this	DET
dti-1401	32	23	article	article	NOUN
dti-1401	32	24	.	.	PUNCT
dti-1401	33	1	declaration	declaration	NOUN
dti-1401	33	2	of	of	ADP
dti-1401	33	3	conflicting	conflicting	ADJ
dti-1401	33	4	interests	interest	NOUN
dti-1401	33	5	:	:	PUNCT
dti-1401	33	6	the	the	DET
dti-1401	33	7	author(s	author(s	NOUN
dti-1401	33	8	)	)	PUNCT
dti-1401	33	9	declared	declare	VERB
dti-1401	33	10	no	no	DET
dti-1401	33	11	potential	potential	ADJ
dti-1401	33	12	conflicts	conflict	NOUN
dti-1401	33	13	of	of	ADP
dti-1401	33	14	interest	interest	NOUN
dti-1401	33	15	with	with	ADP
dti-1401	33	16	respect	respect	NOUN
dti-1401	33	17	to	to	ADP
dti-1401	33	18	the	the	DET
dti-1401	33	19	research	research	NOUN
dti-1401	33	20	,	,	PUNCT
dti-1401	33	21	authorship	authorship	NOUN
dti-1401	33	22	,	,	PUNCT
dti-1401	33	23	and/or	and/or	CCONJ
dti-1401	33	24	publication	publication	NOUN
dti-1401	33	25	of	of	ADP
dti-1401	33	26	this	this	DET
dti-1401	33	27	article	article	NOUN
dti-1401	33	28	.	.	PUNCT
dti-1401	34	1	corresponding	correspond	VERB
dti-1401	34	2	author	author	NOUN
dti-1401	34	3	:	:	PUNCT
dti-1401	34	4	jagannadha	jagannadha	PROPN
dti-1401	34	5	avasarala	avasarala	PROPN
dti-1401	34	6	,	,	PUNCT
dti-1401	34	7	greenville	greenville	PROPN
dti-1401	34	8	health	health	NOUN
dti-1401	34	9	system	system	NOUN
dti-1401	34	10	,	,	PUNCT
dti-1401	34	11	200	200	NUM
dti-1401	34	12	b	b	NOUN
dti-1401	34	13	patewood	patewood	NOUN
dti-1401	34	14	drive	drive	NOUN
dti-1401	34	15	,	,	PUNCT
dti-1401	34	16	bldg	bldg	PROPN
dti-1401	34	17	b	b	PROPN
dti-1401	34	18	,	,	PUNCT
dti-1401	34	19	greenville	greenville	PROPN
dti-1401	34	20	,	,	PUNCT
dti-1401	34	21	sc	sc	PROPN
dti-1401	34	22	29615	29615	NUM
dti-1401	34	23	,	,	PUNCT
dti-1401	34	24	usa	usa	PROPN
dti-1401	34	25	.	.	PROPN
dti-1401	34	26	email	email	NOUN
dti-1401	34	27	:	:	PUNCT
dti-1401	34	28	javasarala@ghs.org	javasarala@ghs.org	ADJ
dti-1401	34	29	785136	785136	NUM
dti-1401	35	1	dti0010.1177/1177392818785136drug	dti0010.1177/1177392818785136drug	PROPN
dti-1401	35	2	target	target	NOUN
dti-1401	35	3	insightsavasarala	insightsavasarala	NOUN
dti-1401	35	4	research	research	NOUN
dti-1401	35	5	-	-	PUNCT
dti-1401	35	6	article2018	article2018	NOUN
dti-1401	35	7	https://uk.sagepub.com/en-gb/journals-permissions	https://uk.sagepub.com/en-gb/journals-permission	NOUN
dti-1401	35	8	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm	NOUN
dti-1401	35	9	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm	NOUN
dti-1401	35	10	mailto:javasarala@ghs.org	mailto:javasarala@ghs.org	PROPN
dti-1401	35	11	2	2	NUM
dti-1401	35	12	drug	drug	NOUN
dti-1401	35	13	target	target	NOUN
dti-1401	35	14	insights	insight	NOUN
dti-1401	35	15	the	the	DET
dti-1401	35	16	case	case	NOUN
dti-1401	35	17	report	report	NOUN
dti-1401	35	18	(	(	PUNCT
dti-1401	35	19	n	n	NOUN
dti-1401	35	20	=	=	NUM
dti-1401	35	21	12	12	NUM
dti-1401	35	22	)	)	PUNCT
dti-1401	35	23	concerning	concern	VERB
dti-1401	35	24	the	the	DET
dti-1401	35	25	central	central	ADJ
dti-1401	35	26	nervous	nervous	ADJ
dti-1401	35	27	system	system	NOUN
dti-1401	35	28	(	(	PUNCT
dti-1401	35	29	cns	cns	NOUN
dti-1401	35	30	)	)	PUNCT
dti-1401	35	31	complications	complication	NOUN
dti-1401	35	32	resulting	result	VERB
dti-1401	35	33	from	from	ADP
dti-1401	35	34	zinbryta	zinbryta	NOUN
dti-1401	35	35	use	use	NOUN
dti-1401	35	36	in	in	ADP
dti-1401	35	37	patients	patient	NOUN
dti-1401	35	38	with	with	ADP
dti-1401	35	39	ms	ms	PROPN
dti-1401	35	40	was	be	AUX
dti-1401	35	41	reported	report	VERB
dti-1401	35	42	by	by	ADP
dti-1401	35	43	the	the	DET
dti-1401	35	44	pharmacovigilance	pharmacovigilance	NOUN
dti-1401	35	45	risk	risk	NOUN
dti-1401	35	46	assessment	assessment	NOUN
dti-1401	35	47	committee	committee	NOUN
dti-1401	35	48	(	(	PUNCT
dti-1401	35	49	prac	prac	NOUN
dti-1401	35	50	)	)	PUNCT
dti-1401	35	51	of	of	ADP
dti-1401	35	52	the	the	DET
dti-1401	35	53	ema	ema	PROPN
dti-1401	35	54	,	,	PUNCT
dti-1401	35	55	which	which	PRON
dti-1401	35	56	include	include	VERB
dti-1401	35	57	9	9	NUM
dti-1401	35	58	from	from	ADP
dti-1401	35	59	germany	germany	PROPN
dti-1401	35	60	,	,	PUNCT
dti-1401	35	61	2	2	NUM
dti-1401	35	62	from	from	ADP
dti-1401	35	63	the	the	DET
dti-1401	35	64	united	united	PROPN
dti-1401	35	65	states	states	PROPN
dti-1401	35	66	,	,	PUNCT
dti-1401	35	67	and	and	CCONJ
dti-1401	35	68	1	1	NUM
dti-1401	35	69	from	from	ADP
dti-1401	35	70	spain	spain	PROPN
dti-1401	35	71	,	,	PUNCT
dti-1401	35	72	and	and	CCONJ
dti-1401	35	73	published	publish	VERB
dti-1401	35	74	on	on	ADP
dti-1401	35	75	march	march	PROPN
dti-1401	35	76	6	6	NUM
dti-1401	35	77	,	,	PUNCT
dti-1401	35	78	2018	2018	NUM
dti-1401	35	79	(	(	PUNCT
dti-1401	35	80	article	article	NOUN
dti-1401	35	81	20	20	NUM
dti-1401	35	82	of	of	ADP
dti-1401	35	83	regulation	regulation	NOUN
dti-1401	35	84	ec	ec	PROPN
dti-1401	35	85	#	#	NOUN
dti-1401	35	86	726/2004	726/2004	NUM
dti-1401	35	87	,	,	PUNCT
dti-1401	35	88	pharmacovigilance	pharmacovigilance	NOUN
dti-1401	35	89	data	datum	NOUN
dti-1401	35	90	)	)	PUNCT
dti-1401	35	91	.	.	PUNCT
dti-1401	36	1	the	the	DET
dti-1401	36	2	predominant	predominant	ADJ
dti-1401	36	3	clinical	clinical	ADJ
dti-1401	36	4	finding	finding	NOUN
dti-1401	36	5	in	in	ADP
dti-1401	36	6	most	most	ADJ
dti-1401	36	7	of	of	ADP
dti-1401	36	8	the	the	DET
dti-1401	36	9	cases	case	NOUN
dti-1401	36	10	that	that	PRON
dti-1401	36	11	led	lead	VERB
dti-1401	36	12	to	to	ADP
dti-1401	36	13	the	the	DET
dti-1401	36	14	cns	cns	PROPN
dti-1401	36	15	complications	complication	NOUN
dti-1401	36	16	was	be	AUX
dti-1401	36	17	from	from	ADP
dti-1401	36	18	dress	dress	NOUN
dti-1401	36	19	syndrome	syndrome	NOUN
dti-1401	36	20	(	(	PUNCT
dti-1401	36	21	cases	case	NOUN
dti-1401	36	22	1	1	NUM
dti-1401	36	23	,	,	PUNCT
dti-1401	36	24	2	2	NUM
dti-1401	36	25	,	,	PUNCT
dti-1401	36	26	6	6	NUM
dti-1401	36	27	,	,	PUNCT
dti-1401	36	28	12	12	NUM
dti-1401	36	29	,	,	PUNCT
dti-1401	36	30	and	and	CCONJ
dti-1401	36	31	probably	probably	ADV
dti-1401	36	32	case	case	NOUN
dti-1401	36	33	3	3	NUM
dti-1401	36	34	)	)	PUNCT
dti-1401	36	35	,	,	PUNCT
dti-1401	36	36	whereas	whereas	SCONJ
dti-1401	36	37	some	some	DET
dti-1401	36	38	cases	case	NOUN
dti-1401	36	39	had	have	VERB
dti-1401	36	40	anti	anti	ADJ
dti-1401	36	41	-	-	ADJ
dti-1401	36	42	nmda	nmda	ADJ
dti-1401	36	43	encephalitis	encephalitis	NOUN
dti-1401	36	44	.	.	PUNCT
dti-1401	37	1	the	the	DET
dti-1401	37	2	zinbryta	zinbryta	NOUN
dti-1401	37	3	dosing	dose	VERB
dti-1401	37	4	for	for	ADP
dti-1401	37	5	the	the	DET
dti-1401	37	6	cases	case	NOUN
dti-1401	37	7	labeled	label	VERB
dti-1401	37	8	1	1	NUM
dti-1401	37	9	through	through	ADP
dti-1401	37	10	5	5	NUM
dti-1401	37	11	included	include	VERB
dti-1401	37	12	the	the	DET
dti-1401	37	13	following	following	NOUN
dti-1401	37	14	:	:	PUNCT
dti-1401	37	15	2	2	NUM
dti-1401	37	16	,	,	PUNCT
dti-1401	37	17	4	4	NUM
dti-1401	37	18	,	,	PUNCT
dti-1401	37	19	2	2	NUM
dti-1401	37	20	,	,	PUNCT
dti-1401	37	21	2	2	NUM
dti-1401	37	22	,	,	PUNCT
dti-1401	37	23	and	and	CCONJ
dti-1401	37	24	8	8	NUM
dti-1401	37	25	,	,	PUNCT
dti-1401	37	26	respectively	respectively	ADV
dti-1401	37	27	(	(	PUNCT
dti-1401	37	28	doses	dose	NOUN
dti-1401	37	29	given	give	VERB
dti-1401	37	30	to	to	ADP
dti-1401	37	31	each	each	DET
dti-1401	37	32	patient	patient	NOUN
dti-1401	37	33	prior	prior	ADV
dti-1401	37	34	to	to	ADP
dti-1401	37	35	clinical	clinical	ADJ
dti-1401	37	36	worsening	worsening	NOUN
dti-1401	37	37	attributed	attribute	VERB
dti-1401	37	38	to	to	ADP
dti-1401	37	39	dress	dress	NOUN
dti-1401	37	40	syndrome	syndrome	NOUN
dti-1401	37	41	)	)	PUNCT
dti-1401	37	42	.	.	PUNCT
dti-1401	38	1	the	the	DET
dti-1401	38	2	pertinent	pertinent	ADJ
dti-1401	38	3	findings	finding	NOUN
dti-1401	38	4	for	for	ADP
dti-1401	38	5	this	this	DET
dti-1401	38	6	case	case	NOUN
dti-1401	38	7	cluster	cluster	NOUN
dti-1401	38	8	included	include	VERB
dti-1401	38	9	the	the	DET
dti-1401	38	10	following	following	NOUN
dti-1401	38	11	—	—	PUNCT
dti-1401	38	12	exanthematous	exanthematous	ADJ
dti-1401	38	13	skin	skin	NOUN
dti-1401	38	14	rash	rash	NOUN
dti-1401	38	15	,	,	PUNCT
dti-1401	38	16	fever	fever	NOUN
dti-1401	38	17	,	,	PUNCT
dti-1401	38	18	altered	alter	VERB
dti-1401	38	19	mental	mental	ADJ
dti-1401	38	20	status	status	NOUN
dti-1401	38	21	,	,	PUNCT
dti-1401	38	22	peripheral	peripheral	ADJ
dti-1401	38	23	eosinophilia	eosinophilia	NOUN
dti-1401	38	24	(	(	PUNCT
dti-1401	38	25	9.3	9.3	NUM
dti-1401	38	26	%	%	NOUN
dti-1401	38	27	that	that	PRON
dti-1401	38	28	increased	increase	VERB
dti-1401	38	29	to	to	ADP
dti-1401	38	30	25.5	25.5	NUM
dti-1401	38	31	%	%	NOUN
dti-1401	38	32	in	in	ADP
dti-1401	38	33	case	case	NOUN
dti-1401	38	34	1	1	NUM
dti-1401	38	35	,	,	PUNCT
dti-1401	38	36	11.4	11.4	NUM
dti-1401	38	37	%	%	NOUN
dti-1401	38	38	for	for	ADP
dti-1401	38	39	case	case	NOUN
dti-1401	38	40	2	2	NUM
dti-1401	38	41	)	)	PUNCT
dti-1401	38	42	,	,	PUNCT
dti-1401	38	43	and	and	CCONJ
dti-1401	38	44	“	"	PUNCT
dti-1401	38	45	ms	ms	PROPN
dti-1401	38	46	relapse	relapse	NOUN
dti-1401	38	47	”	"	PUNCT
dti-1401	38	48	characterized	characterize	VERB
dti-1401	38	49	by	by	ADP
dti-1401	38	50	clinical	clinical	ADJ
dti-1401	38	51	and	and	CCONJ
dti-1401	38	52	radiological	radiological	ADJ
dti-1401	38	53	worsening	worsening	NOUN
dti-1401	38	54	.	.	PUNCT
dti-1401	39	1	brain	brain	NOUN
dti-1401	39	2	biopsies	biopsy	NOUN
dti-1401	39	3	,	,	PUNCT
dti-1401	39	4	where	where	SCONJ
dti-1401	39	5	performed	perform	VERB
dti-1401	39	6	,	,	PUNCT
dti-1401	39	7	showed	show	VERB
dti-1401	39	8	tand	tand	PROPN
dti-1401	39	9	b	b	X
dti-1401	39	10	-	-	PUNCT
dti-1401	39	11	cell	cell	NOUN
dti-1401	39	12	infiltration	infiltration	NOUN
dti-1401	39	13	,	,	PUNCT
dti-1401	39	14	as	as	ADV
dti-1401	39	15	well	well	ADV
dti-1401	39	16	as	as	ADP
dti-1401	39	17	plasma	plasma	NOUN
dti-1401	39	18	cell	cell	NOUN
dti-1401	39	19	and	and	CCONJ
dti-1401	39	20	eosinophilic	eosinophilic	ADJ
dti-1401	39	21	granulocytes	granulocyte	NOUN
dti-1401	39	22	.	.	PUNCT
dti-1401	40	1	in	in	ADP
dti-1401	40	2	all	all	PRON
dti-1401	40	3	,	,	PUNCT
dti-1401	40	4	at	at	ADV
dti-1401	40	5	least	least	ADJ
dti-1401	40	6	3	3	NUM
dti-1401	40	7	patients	patient	NOUN
dti-1401	40	8	died	die	VERB
dti-1401	40	9	,	,	PUNCT
dti-1401	40	10	in	in	ADP
dti-1401	40	11	the	the	DET
dti-1401	40	12	reported	report	VERB
dti-1401	40	13	cohort	cohort	NOUN
dti-1401	40	14	.	.	PUNCT
dti-1401	41	1	dress	dress	NOUN
dti-1401	41	2	syndrome	syndrome	NOUN
dti-1401	41	3	or	or	CCONJ
dti-1401	41	4	drug	drug	NOUN
dti-1401	41	5	reaction	reaction	NOUN
dti-1401	41	6	with	with	ADP
dti-1401	41	7	eosinophilia	eosinophilia	PROPN
dti-1401	41	8	and	and	CCONJ
dti-1401	41	9	systemic	systemic	ADJ
dti-1401	41	10	symptoms	symptom	NOUN
dti-1401	41	11	is	be	AUX
dti-1401	41	12	a	a	DET
dti-1401	41	13	life	life	NOUN
dti-1401	41	14	-	-	PUNCT
dti-1401	41	15	threatening	threaten	VERB
dti-1401	41	16	disease	disease	NOUN
dti-1401	41	17	with	with	ADP
dti-1401	41	18	cutaneous	cutaneous	ADJ
dti-1401	41	19	manifestations	manifestation	NOUN
dti-1401	41	20	and	and	CCONJ
dti-1401	41	21	internal	internal	ADJ
dti-1401	41	22	organ	organ	NOUN
dti-1401	41	23	involvement2	involvement2	NOUN
dti-1401	41	24	;	;	PUNCT
dti-1401	41	25	it	it	PRON
dti-1401	41	26	carries	carry	VERB
dti-1401	41	27	a	a	DET
dti-1401	41	28	mortality	mortality	NOUN
dti-1401	41	29	rate	rate	NOUN
dti-1401	41	30	of	of	ADP
dti-1401	41	31	approximately	approximately	ADV
dti-1401	41	32	10	10	NUM
dti-1401	41	33	%	%	NOUN
dti-1401	41	34	.	.	PUNCT
dti-1401	42	1	the	the	DET
dti-1401	42	2	time	time	NOUN
dti-1401	42	3	of	of	ADP
dti-1401	42	4	symptom	symptom	NOUN
dti-1401	42	5	onset	onset	VERB
dti-1401	42	6	varies	varie	NOUN
dti-1401	42	7	,	,	PUNCT
dti-1401	42	8	following	follow	VERB
dti-1401	42	9	drug	drug	NOUN
dti-1401	42	10	exposure	exposure	NOUN
dti-1401	42	11	,	,	PUNCT
dti-1401	42	12	and	and	CCONJ
dti-1401	42	13	can	can	AUX
dti-1401	42	14	be	be	AUX
dti-1401	42	15	between	between	ADP
dti-1401	42	16	2	2	NUM
dti-1401	42	17	and	and	CCONJ
dti-1401	42	18	8	8	NUM
dti-1401	42	19	weeks	week	NOUN
dti-1401	42	20	.	.	PUNCT
dti-1401	43	1	the	the	DET
dti-1401	43	2	incidence	incidence	NOUN
dti-1401	43	3	is	be	AUX
dti-1401	43	4	unclear	unclear	ADJ
dti-1401	43	5	and	and	CCONJ
dti-1401	43	6	overall	overall	ADJ
dti-1401	43	7	population	population	NOUN
dti-1401	43	8	risk	risk	NOUN
dti-1401	43	9	varies	vary	VERB
dti-1401	43	10	between	between	ADP
dti-1401	43	11	1	1	NUM
dti-1401	43	12	in	in	ADP
dti-1401	43	13	1000	1000	NUM
dti-1401	43	14	and	and	CCONJ
dti-1401	43	15	1	1	NUM
dti-1401	43	16	in	in	ADP
dti-1401	43	17	10	10	NUM
dti-1401	43	18	000	000	NUM
dti-1401	43	19	drug	drug	NOUN
dti-1401	43	20	exposures.3,4	exposures.3,4	ADJ
dti-1401	43	21	in	in	ADP
dti-1401	43	22	general	general	ADJ
dti-1401	43	23	,	,	PUNCT
dti-1401	43	24	dress	dress	NOUN
dti-1401	43	25	syndrome	syndrome	NOUN
dti-1401	43	26	is	be	AUX
dti-1401	43	27	probably	probably	ADV
dti-1401	43	28	missed	miss	VERB
dti-1401	43	29	or	or	CCONJ
dti-1401	43	30	overlooked	overlook	VERB
dti-1401	43	31	owing	owe	VERB
dti-1401	43	32	to	to	ADP
dti-1401	43	33	its	its	PRON
dti-1401	43	34	varied	varied	ADJ
dti-1401	43	35	presentation	presentation	NOUN
dti-1401	43	36	and	and	CCONJ
dti-1401	43	37	a	a	DET
dti-1401	43	38	lack	lack	NOUN
dti-1401	43	39	of	of	ADP
dti-1401	43	40	understanding	understanding	NOUN
dti-1401	43	41	of	of	ADP
dti-1401	43	42	its	its	PRON
dti-1401	43	43	manifestations	manifestation	NOUN
dti-1401	43	44	among	among	ADP
dti-1401	43	45	physicians	physician	NOUN
dti-1401	43	46	.	.	PUNCT
dti-1401	44	1	typical	typical	ADJ
dti-1401	44	2	features	feature	NOUN
dti-1401	44	3	of	of	ADP
dti-1401	44	4	dress	dress	NOUN
dti-1401	44	5	syndrome	syndrome	NOUN
dti-1401	44	6	(	(	PUNCT
dti-1401	44	7	figure	figure	NOUN
dti-1401	44	8	1	1	NUM
dti-1401	44	9	)	)	PUNCT
dti-1401	44	10	include	include	VERB
dti-1401	44	11	fever	fever	NOUN
dti-1401	44	12	,	,	PUNCT
dti-1401	44	13	widespread	widespread	ADJ
dti-1401	44	14	cutaneous	cutaneous	ADJ
dti-1401	44	15	lesions	lesion	NOUN
dti-1401	44	16	,	,	PUNCT
dti-1401	44	17	eosinophilia,5	eosinophilia,5	ADJ
dti-1401	44	18	and	and	CCONJ
dti-1401	44	19	atypical	atypical	ADJ
dti-1401	44	20	lymphocytosis,6	lymphocytosis,6	NOUN
dti-1401	44	21	as	as	ADV
dti-1401	44	22	well	well	ADV
dti-1401	44	23	as	as	ADP
dti-1401	44	24	hepatic	hepatic	ADJ
dti-1401	44	25	injury,2	injury,2	NOUN
dti-1401	44	26	lymphadenopathy	lymphadenopathy	ADJ
dti-1401	44	27	,	,	PUNCT
dti-1401	44	28	and	and	CCONJ
dti-1401	44	29	renal	renal	ADJ
dti-1401	44	30	failure.2	failure.2	ADJ
dti-1401	44	31	additional	additional	ADJ
dti-1401	44	32	organ	organ	NOUN
dti-1401	44	33	involvement	involvement	NOUN
dti-1401	44	34	includes	include	VERB
dti-1401	44	35	lung,2	lung,2	NOUN
dti-1401	44	36	cardiac,7	cardiac,7	NOUN
dti-1401	44	37	and	and	CCONJ
dti-1401	44	38	cns	cns	PROPN
dti-1401	44	39	involvement	involvement	NOUN
dti-1401	44	40	characterized	characterize	VERB
dti-1401	44	41	as	as	ADP
dti-1401	44	42	meningitis	meningitis	NOUN
dti-1401	44	43	or	or	CCONJ
dti-1401	44	44	encephalitis.8	encephalitis.8	PROPN
dti-1401	44	45	therefore	therefore	ADV
dti-1401	44	46	,	,	PUNCT
dti-1401	44	47	familiarity	familiarity	NOUN
dti-1401	44	48	with	with	ADP
dti-1401	44	49	the	the	DET
dti-1401	44	50	clinical	clinical	ADJ
dti-1401	44	51	features	feature	NOUN
dti-1401	44	52	help	help	VERB
dti-1401	44	53	clinicians	clinician	NOUN
dti-1401	44	54	pinpoint	pinpoint	VERB
dti-1401	44	55	the	the	DET
dti-1401	44	56	diagnosis	diagnosis	NOUN
dti-1401	44	57	,	,	PUNCT
dti-1401	44	58	and	and	CCONJ
dti-1401	44	59	further	far	ADV
dti-1401	44	60	worsening	worsen	VERB
dti-1401	44	61	of	of	ADP
dti-1401	44	62	symptoms	symptom	NOUN
dti-1401	44	63	can	can	AUX
dti-1401	44	64	be	be	AUX
dti-1401	44	65	mitigated	mitigate	VERB
dti-1401	44	66	by	by	ADP
dti-1401	44	67	discontinuation	discontinuation	NOUN
dti-1401	44	68	of	of	ADP
dti-1401	44	69	the	the	DET
dti-1401	44	70	offending	offending	ADJ
dti-1401	44	71	agent	agent	NOUN
dti-1401	44	72	.	.	PUNCT
dti-1401	45	1	sometimes	sometimes	ADV
dti-1401	45	2	this	this	PRON
dti-1401	45	3	may	may	AUX
dti-1401	45	4	be	be	AUX
dti-1401	45	5	difficult	difficult	ADJ
dti-1401	45	6	if	if	SCONJ
dti-1401	45	7	multiple	multiple	ADJ
dti-1401	45	8	drugs	drug	NOUN
dti-1401	45	9	are	be	AUX
dti-1401	45	10	used	use	VERB
dti-1401	45	11	but	but	CCONJ
dti-1401	45	12	understanding	understanding	NOUN
dti-1401	45	13	of	of	ADP
dti-1401	45	14	triggers	trigger	NOUN
dti-1401	45	15	,	,	PUNCT
dti-1401	45	16	time	time	NOUN
dti-1401	45	17	course	course	NOUN
dti-1401	45	18	,	,	PUNCT
dti-1401	45	19	and	and	CCONJ
dti-1401	45	20	clinical	clinical	ADJ
dti-1401	45	21	manifestations	manifestation	NOUN
dti-1401	45	22	including	include	VERB
dti-1401	45	23	dermal	dermal	NOUN
dti-1401	45	24	,	,	PUNCT
dti-1401	45	25	internal	internal	ADJ
dti-1401	45	26	organ	organ	NOUN
dti-1401	45	27	,	,	PUNCT
dti-1401	45	28	and	and	CCONJ
dti-1401	45	29	laboratory	laboratory	NOUN
dti-1401	45	30	abnormalities	abnormality	NOUN
dti-1401	45	31	can	can	AUX
dti-1401	45	32	help	help	VERB
dti-1401	45	33	nail	nail	VERB
dti-1401	45	34	the	the	DET
dti-1401	45	35	diagnosis	diagnosis	NOUN
dti-1401	45	36	.	.	PUNCT
dti-1401	46	1	viral	viral	ADJ
dti-1401	46	2	reactivation	reactivation	NOUN
dti-1401	46	3	,	,	PUNCT
dti-1401	46	4	particularly	particularly	ADV
dti-1401	46	5	hhv-6	hhv-6	NOUN
dti-1401	46	6	reactivation	reactivation	NOUN
dti-1401	46	7	,	,	PUNCT
dti-1401	46	8	is	be	AUX
dti-1401	46	9	thought	think	VERB
dti-1401	46	10	to	to	PART
dti-1401	46	11	play	play	VERB
dti-1401	46	12	an	an	DET
dti-1401	46	13	important	important	ADJ
dti-1401	46	14	role	role	NOUN
dti-1401	46	15	in	in	ADP
dti-1401	46	16	dress	dress	NOUN
dti-1401	46	17	syndrome	syndrome	NOUN
dti-1401	46	18	,	,	PUNCT
dti-1401	46	19	as	as	SCONJ
dti-1401	46	20	seen	see	VERB
dti-1401	46	21	in	in	ADP
dti-1401	46	22	valproic	valproic	ADJ
dti-1401	46	23	acid	acid	NOUN
dti-1401	46	24	use	use	NOUN
dti-1401	46	25	,	,	PUNCT
dti-1401	46	26	for	for	ADP
dti-1401	46	27	example.9	example.9	NOUN
dti-1401	46	28	in	in	ADP
dti-1401	46	29	addition	addition	NOUN
dti-1401	46	30	,	,	PUNCT
dti-1401	46	31	whether	whether	SCONJ
dti-1401	46	32	the	the	DET
dti-1401	46	33	patients	patient	NOUN
dti-1401	46	34	who	who	PRON
dti-1401	46	35	developed	develop	VERB
dti-1401	46	36	dress	dress	NOUN
dti-1401	46	37	syndrome	syndrome	NOUN
dti-1401	46	38	in	in	ADP
dti-1401	46	39	the	the	DET
dti-1401	46	40	cohort	cohort	NOUN
dti-1401	46	41	of	of	ADP
dti-1401	46	42	patients	patient	NOUN
dti-1401	46	43	with	with	ADP
dti-1401	46	44	ms	ms	PROPN
dti-1401	46	45	also	also	ADV
dti-1401	46	46	had	have	AUX
dti-1401	46	47	other	other	ADJ
dti-1401	46	48	increased	increase	VERB
dti-1401	46	49	risk	risk	NOUN
dti-1401	46	50	factors	factor	NOUN
dti-1401	46	51	such	such	ADJ
dti-1401	46	52	as	as	ADP
dti-1401	46	53	hla	hla	PROPN
dti-1401	46	54	class	class	PROPN
dti-1401	46	55	ii	ii	PROPN
dti-1401	46	56	alleles	allele	NOUN
dti-1401	46	57	would	would	AUX
dti-1401	46	58	be	be	AUX
dti-1401	46	59	worth	worth	ADJ
dti-1401	46	60	exploring	explore	VERB
dti-1401	46	61	.	.	PUNCT
dti-1401	47	1	many	many	ADJ
dti-1401	47	2	studies	study	NOUN
dti-1401	47	3	have	have	AUX
dti-1401	47	4	reported	report	VERB
dti-1401	47	5	dress	dress	NOUN
dti-1401	47	6	syndrome	syndrome	NOUN
dti-1401	47	7	patients	patient	NOUN
dti-1401	47	8	with	with	ADP
dti-1401	47	9	genetic	genetic	ADJ
dti-1401	47	10	predisposition	predisposition	NOUN
dti-1401	47	11	linked	link	VERB
dti-1401	47	12	to	to	ADP
dti-1401	47	13	specific	specific	ADJ
dti-1401	47	14	drugs	drug	NOUN
dti-1401	47	15	and	and	CCONJ
dti-1401	47	16	one	one	NUM
dti-1401	47	17	wonders	wonder	NOUN
dti-1401	47	18	if	if	SCONJ
dti-1401	47	19	zinbryta	zinbryta	NOUN
dti-1401	47	20	use	use	NOUN
dti-1401	47	21	,	,	PUNCT
dti-1401	47	22	dress	dress	NOUN
dti-1401	47	23	syndrome	syndrome	NOUN
dti-1401	47	24	,	,	PUNCT
dti-1401	47	25	and	and	CCONJ
dti-1401	47	26	hla	hla	PROPN
dti-1401	47	27	class	class	PROPN
dti-1401	47	28	ii	ii	PROPN
dti-1401	47	29	alleles	allele	NOUN
dti-1401	47	30	were	be	AUX
dti-1401	47	31	linked	link	VERB
dti-1401	47	32	as	as	ADV
dti-1401	47	33	well	well	ADV
dti-1401	47	34	.	.	PUNCT
dti-1401	48	1	author	author	NOUN
dti-1401	48	2	contributions	contribution	NOUN
dti-1401	48	3	ja	ja	PROPN
dti-1401	48	4	is	be	AUX
dti-1401	48	5	the	the	DET
dti-1401	48	6	sole	sole	ADJ
dti-1401	48	7	author	author	NOUN
dti-1401	48	8	,	,	PUNCT
dti-1401	48	9	therefore	therefore	ADV
dti-1401	48	10	,	,	PUNCT
dti-1401	48	11	the	the	DET
dti-1401	48	12	concept	concept	NOUN
dti-1401	48	13	,	,	PUNCT
dti-1401	48	14	analysis	analysis	NOUN
dti-1401	48	15	,	,	PUNCT
dti-1401	48	16	layout	layout	NOUN
dti-1401	48	17	and	and	CCONJ
dti-1401	48	18	presentation	presentation	NOUN
dti-1401	48	19	is	be	AUX
dti-1401	48	20	all	all	PRON
dti-1401	48	21	done	do	VERB
dti-1401	48	22	by	by	ADP
dti-1401	48	23	ja	ja	PROPN
dti-1401	48	24	.	.	PUNCT
dti-1401	49	1	references	reference	NOUN
dti-1401	49	2	1	1	NUM
dti-1401	49	3	.	.	PUNCT
dti-1401	49	4	giovannoni	giovannoni	PROPN
dti-1401	49	5	g	g	PROPN
dti-1401	49	6	,	,	PUNCT
dti-1401	49	7	kappos	kappos	PROPN
dti-1401	49	8	l	l	PROPN
dti-1401	49	9	,	,	PUNCT
dti-1401	49	10	gold	gold	NOUN
dti-1401	49	11	r	r	NOUN
dti-1401	49	12	,	,	PUNCT
dti-1401	49	13	et	et	PROPN
dti-1401	49	14	al	al	PROPN
dti-1401	49	15	.	.	PROPN
dti-1401	49	16	safety	safety	NOUN
dti-1401	49	17	and	and	CCONJ
dti-1401	49	18	tolerability	tolerability	NOUN
dti-1401	49	19	profile	profile	NOUN
dti-1401	49	20	of	of	ADP
dti-1401	49	21	daclizumab	daclizumab	NOUN
dti-1401	49	22	in	in	ADP
dti-1401	49	23	patients	patient	NOUN
dti-1401	49	24	with	with	ADP
dti-1401	49	25	relapsing	relapse	VERB
dti-1401	49	26	-	-	PUNCT
dti-1401	49	27	remitting	remit	VERB
dti-1401	49	28	multiple	multiple	ADJ
dti-1401	49	29	sclerosis	sclerosis	NOUN
dti-1401	49	30	:	:	PUNCT
dti-1401	49	31	an	an	DET
dti-1401	49	32	integrated	integrated	ADJ
dti-1401	49	33	analysis	analysis	NOUN
dti-1401	49	34	of	of	ADP
dti-1401	49	35	clinical	clinical	ADJ
dti-1401	49	36	studies	study	NOUN
dti-1401	49	37	.	.	PUNCT
dti-1401	50	1	mult	mult	PROPN
dti-1401	50	2	scler	scler	PROPN
dti-1401	50	3	relat	relat	PROPN
dti-1401	50	4	dis	dis	PROPN
dti-1401	50	5	.	.	PUNCT
dti-1401	51	1	2016;9:36–46	2016;9:36–46	NUM
dti-1401	51	2	.	.	NOUN
dti-1401	51	3	2	2	NUM
dti-1401	51	4	.	.	X
dti-1401	52	1	chen	chen	PROPN
dti-1401	52	2	yc	yc	PROPN
dti-1401	52	3	,	,	PUNCT
dti-1401	52	4	chiu	chiu	PROPN
dti-1401	52	5	hc	hc	PROPN
dti-1401	52	6	,	,	PUNCT
dti-1401	52	7	chu	chu	PROPN
dti-1401	52	8	cy	cy	PROPN
dti-1401	52	9	.	.	PROPN
dti-1401	52	10	drug	drug	NOUN
dti-1401	52	11	reaction	reaction	NOUN
dti-1401	52	12	with	with	ADP
dti-1401	52	13	eosinophilia	eosinophilia	PROPN
dti-1401	52	14	and	and	CCONJ
dti-1401	52	15	systemic	systemic	ADJ
dti-1401	52	16	symptoms	symptom	NOUN
dti-1401	52	17	.	.	PUNCT
dti-1401	53	1	a	a	DET
dti-1401	53	2	retrospective	retrospective	ADJ
dti-1401	53	3	study	study	NOUN
dti-1401	53	4	of	of	ADP
dti-1401	53	5	60	60	NUM
dti-1401	53	6	cases	case	NOUN
dti-1401	53	7	.	.	PUNCT
dti-1401	54	1	arch	arch	ADJ
dti-1401	54	2	dermatol	dermatol	NOUN
dti-1401	54	3	.	.	PUNCT
dti-1401	55	1	2010;146:1373–1379	2010;146:1373–1379	NUM
dti-1401	55	2	.	.	PUNCT
dti-1401	56	1	3	3	X
dti-1401	56	2	.	.	X
dti-1401	56	3	chiou	chiou	PROPN
dti-1401	56	4	cc	cc	PROPN
dti-1401	56	5	,	,	PUNCT
dti-1401	56	6	yang	yang	PROPN
dti-1401	56	7	lc	lc	PROPN
dti-1401	56	8	,	,	PUNCT
dti-1401	56	9	hung	hang	VERB
dti-1401	56	10	si	si	PROPN
dti-1401	56	11	,	,	PUNCT
dti-1401	56	12	et	et	PROPN
dti-1401	56	13	al	al	PROPN
dti-1401	56	14	.	.	PROPN
dti-1401	56	15	clinicopathological	clinicopathological	ADJ
dti-1401	56	16	features	feature	NOUN
dti-1401	56	17	and	and	CCONJ
dti-1401	56	18	prognosis	prognosis	NOUN
dti-1401	56	19	of	of	ADP
dti-1401	56	20	drug	drug	NOUN
dti-1401	56	21	rash	rash	NOUN
dti-1401	56	22	with	with	ADP
dti-1401	56	23	eosinophilia	eosinophilia	PROPN
dti-1401	56	24	and	and	CCONJ
dti-1401	56	25	systemic	systemic	ADJ
dti-1401	56	26	symptoms	symptom	NOUN
dti-1401	56	27	:	:	PUNCT
dti-1401	56	28	a	a	DET
dti-1401	56	29	study	study	NOUN
dti-1401	56	30	of	of	ADP
dti-1401	56	31	30	30	NUM
dti-1401	56	32	cases	case	NOUN
dti-1401	56	33	in	in	ADP
dti-1401	56	34	taiwan	taiwan	PROPN
dti-1401	56	35	.	.	PUNCT
dti-1401	57	1	j	j	PROPN
dti-1401	57	2	eur	eur	PROPN
dti-1401	57	3	acad	acad	PROPN
dti-1401	57	4	dermatol	dermatol	NOUN
dti-1401	57	5	venereol	venereol	NOUN
dti-1401	57	6	.	.	PUNCT
dti-1401	58	1	2008;22:1044–1049	2008;22:1044–1049	X
dti-1401	58	2	.	.	PUNCT
dti-1401	59	1	4	4	NUM
dti-1401	59	2	.	.	NOUN
dti-1401	59	3	shiohara	shiohara	PROPN
dti-1401	59	4	t	t	PROPN
dti-1401	59	5	,	,	PUNCT
dti-1401	59	6	kano	kano	PROPN
dti-1401	59	7	y.	y.	PROPN
dti-1401	59	8	review	review	PROPN
dti-1401	59	9	of	of	ADP
dti-1401	59	10	drug	drug	NOUN
dti-1401	59	11	-	-	PUNCT
dti-1401	59	12	induced	induce	VERB
dti-1401	59	13	hypersensitivity	hypersensitivity	NOUN
dti-1401	59	14	:	:	PUNCT
dti-1401	59	15	special	special	ADJ
dti-1401	59	16	emphasis	emphasis	NOUN
dti-1401	59	17	on	on	ADP
dti-1401	59	18	drug	drug	NOUN
dti-1401	59	19	-	-	PUNCT
dti-1401	59	20	induced	induce	VERB
dti-1401	59	21	hypersensitivity	hypersensitivity	NOUN
dti-1401	59	22	syndrome	syndrome	NOUN
dti-1401	59	23	.	.	PUNCT
dti-1401	60	1	expert	expert	ADJ
dti-1401	60	2	dermatol	dermatol	NOUN
dti-1401	60	3	.	.	PUNCT
dti-1401	61	1	2012;7:539–547	2012;7:539–547	X
dti-1401	61	2	.	.	PUNCT
dti-1401	62	1	5	5	NUM
dti-1401	62	2	.	.	NOUN
dti-1401	62	3	cacoub	cacoub	PROPN
dti-1401	62	4	p	p	NOUN
dti-1401	62	5	,	,	PUNCT
dti-1401	62	6	musette	musette	PROPN
dti-1401	62	7	p	p	X
dti-1401	62	8	,	,	PUNCT
dti-1401	62	9	descamps	descamp	VERB
dti-1401	62	10	v	v	NOUN
dti-1401	62	11	,	,	PUNCT
dti-1401	62	12	et	et	PROPN
dti-1401	62	13	al	al	PROPN
dti-1401	62	14	.	.	PUNCT
dti-1401	63	1	the	the	DET
dti-1401	63	2	dress	dress	NOUN
dti-1401	63	3	syndrome	syndrome	NOUN
dti-1401	63	4	:	:	PUNCT
dti-1401	63	5	a	a	DET
dti-1401	63	6	literature	literature	NOUN
dti-1401	63	7	review	review	NOUN
dti-1401	63	8	.	.	PUNCT
dti-1401	63	9	am	be	AUX
dti-1401	63	10	j	j	PROPN
dti-1401	63	11	med	med	PROPN
dti-1401	63	12	.	.	PUNCT
dti-1401	63	13	2011;124:588–597	2011;124:588–597	NUM
dti-1401	63	14	.	.	PUNCT
dti-1401	64	1	6	6	NUM
dti-1401	64	2	.	.	X
dti-1401	64	3	kardaun	kardaun	PROPN
dti-1401	64	4	sh	sh	PROPN
dti-1401	64	5	,	,	PUNCT
dti-1401	64	6	sekula	sekula	VERB
dti-1401	64	7	p	p	PRON
dti-1401	64	8	,	,	PUNCT
dti-1401	64	9	valeyrie	valeyrie	NOUN
dti-1401	64	10	-	-	PUNCT
dti-1401	64	11	allanore	allanore	NOUN
dti-1401	64	12	l	l	NOUN
dti-1401	64	13	,	,	PUNCT
dti-1401	64	14	et	et	PROPN
dti-1401	64	15	al	al	PROPN
dti-1401	64	16	.	.	PROPN
dti-1401	64	17	drug	drug	NOUN
dti-1401	64	18	reaction	reaction	NOUN
dti-1401	64	19	with	with	ADP
dti-1401	64	20	eosinophilia	eosinophilia	PROPN
dti-1401	64	21	and	and	CCONJ
dti-1401	64	22	systemic	systemic	ADJ
dti-1401	64	23	symptoms	symptom	NOUN
dti-1401	64	24	(	(	PUNCT
dti-1401	64	25	dress	dress	NOUN
dti-1401	64	26	):	):	PUNCT
dti-1401	64	27	an	an	DET
dti-1401	64	28	original	original	ADJ
dti-1401	64	29	multisystem	multisystem	NOUN
dti-1401	64	30	adverse	adverse	ADJ
dti-1401	64	31	drug	drug	NOUN
dti-1401	64	32	reaction	reaction	NOUN
dti-1401	64	33	.	.	PUNCT
dti-1401	65	1	results	result	NOUN
dti-1401	65	2	from	from	ADP
dti-1401	65	3	the	the	DET
dti-1401	65	4	prospective	prospective	ADJ
dti-1401	65	5	regiscar	regiscar	NOUN
dti-1401	65	6	study	study	NOUN
dti-1401	65	7	.	.	PUNCT
dti-1401	66	1	br	br	PROPN
dti-1401	66	2	j	j	PROPN
dti-1401	66	3	dermatol	dermatol	NOUN
dti-1401	66	4	.	.	PUNCT
dti-1401	67	1	2013;169:1071–1080	2013;169:1071–1080	NUM
dti-1401	67	2	.	.	PUNCT
dti-1401	68	1	7	7	X
dti-1401	68	2	.	.	X
dti-1401	68	3	bourgeois	bourgeois	ADJ
dti-1401	68	4	gp	gp	NOUN
dti-1401	68	5	,	,	PUNCT
dti-1401	68	6	cafardi	cafardi	PROPN
dti-1401	68	7	ja	ja	PROPN
dti-1401	68	8	,	,	PUNCT
dti-1401	68	9	groysman	groysman	NOUN
dti-1401	68	10	v	v	NOUN
dti-1401	68	11	,	,	PUNCT
dti-1401	68	12	pamboukian	pamboukian	PROPN
dti-1401	68	13	sv	sv	PROPN
dti-1401	68	14	,	,	PUNCT
dti-1401	68	15	kirklin	kirklin	PROPN
dti-1401	68	16	jk	jk	PROPN
dti-1401	68	17	,	,	PUNCT
dti-1401	68	18	andea	andea	PROPN
dti-1401	68	19	aa	aa	PROPN
dti-1401	68	20	.	.	PUNCT
dti-1401	69	1	fulminant	fulminant	PROPN
dti-1401	69	2	myocarditis	myocarditis	PROPN
dti-1401	69	3	as	as	ADP
dti-1401	69	4	a	a	DET
dti-1401	69	5	late	late	ADJ
dti-1401	69	6	sequela	sequela	NOUN
dti-1401	69	7	of	of	ADP
dti-1401	69	8	dress	dress	NOUN
dti-1401	69	9	:	:	PUNCT
dti-1401	69	10	two	two	NUM
dti-1401	69	11	cases	case	NOUN
dti-1401	69	12	.	.	PUNCT
dti-1401	70	1	j	j	PROPN
dti-1401	70	2	am	be	AUX
dti-1401	70	3	acad	acad	ADJ
dti-1401	70	4	dermatol	dermatol	NOUN
dti-1401	70	5	.	.	PUNCT
dti-1401	71	1	2011;65:889–890	2011;65:889–890	NOUN
dti-1401	71	2	.	.	NOUN
dti-1401	72	1	8	8	NUM
dti-1401	72	2	.	.	PUNCT
dti-1401	73	1	husain	husain	PROPN
dti-1401	73	2	z	z	PROPN
dti-1401	73	3	,	,	PUNCT
dti-1401	73	4	reddy	reddy	PROPN
dti-1401	73	5	by	by	ADP
dti-1401	73	6	,	,	PUNCT
dti-1401	73	7	schwartz	schwartz	PROPN
dti-1401	73	8	ra	ra	PROPN
dti-1401	73	9	.	.	PUNCT
dti-1401	74	1	dress	dress	PROPN
dti-1401	74	2	syndrome	syndrome	PROPN
dti-1401	74	3	part	part	NOUN
dti-1401	74	4	1	1	NUM
dti-1401	74	5	.	.	PUNCT
dti-1401	75	1	clinical	clinical	ADJ
dti-1401	75	2	perspectives	perspective	NOUN
dti-1401	75	3	.	.	PUNCT
dti-1401	76	1	j	j	PROPN
dti-1401	76	2	am	be	AUX
dti-1401	76	3	acad	acad	ADJ
dti-1401	76	4	dermatol	dermatol	NOUN
dti-1401	76	5	.	.	PUNCT
dti-1401	77	1	2013;68:693e1	2013;68:693e1	NUM
dti-1401	77	2	-	-	SYM
dti-1401	77	3	639e14	639e14	NOUN
dti-1401	77	4	.	.	NOUN
dti-1401	78	1	9	9	X
dti-1401	78	2	.	.	X
dti-1401	78	3	mardivirin	mardivirin	NOUN
dti-1401	78	4	l	l	PROPN
dti-1401	78	5	,	,	PUNCT
dti-1401	78	6	lacroix	lacroix	NOUN
dti-1401	78	7	ad	ad	NOUN
dti-1401	78	8	,	,	PUNCT
dti-1401	78	9	descamps	descamp	VERB
dti-1401	78	10	v	v	NOUN
dti-1401	78	11	,	,	PUNCT
dti-1401	78	12	ranger	ranger	NOUN
dti-1401	78	13	-	-	PUNCT
dti-1401	78	14	rogez	rogez	NOUN
dti-1401	78	15	s.	s.	PROPN
dti-1401	78	16	augmentation	augmentation	PROPN
dti-1401	78	17	de	de	X
dti-1401	78	18	la	la	PROPN
dti-1401	78	19	replication	replication	NOUN
dti-1401	78	20	in	in	ADP
dti-1401	78	21	vitro	vitro	X
dti-1401	78	22	de	de	X
dti-1401	78	23	i’herpesvirus	i’herpesvirus	PROPN
dti-1401	78	24	humain	humain	NOUN
dti-1401	78	25	6	6	NUM
dti-1401	78	26	en	en	ADP
dti-1401	78	27	presence	presence	NOUN
dti-1401	78	28	de	de	ADP
dti-1401	78	29	valproate	valproate	ADJ
dti-1401	78	30	de	de	X
dti-1401	78	31	sodium	sodium	NOUN
dti-1401	78	32	.	.	PUNCT
dti-1401	79	1	virologie	virologie	NOUN
dti-1401	79	2	.	.	PUNCT
dti-1401	80	1	2007;11:1–3	2007;11:1–3	NUM
dti-1401	80	2	.	.	PUNCT
dti-1401	81	1	figure	figure	NOUN
dti-1401	81	2	1	1	NUM
dti-1401	81	3	.	.	PUNCT
dti-1401	81	4	salient	salient	NOUN
dti-1401	81	5	features	feature	NOUN
dti-1401	81	6	of	of	ADP
dti-1401	81	7	dress	dress	NOUN
dti-1401	81	8	syndrome	syndrome	NOUN
dti-1401	81	9	,	,	PUNCT
dti-1401	81	10	typically	typically	ADV
dti-1401	81	11	seen	see	VERB
dti-1401	81	12	in	in	ADP
dti-1401	81	13	the	the	DET
dti-1401	81	14	context	context	NOUN
dti-1401	81	15	of	of	ADP
dti-1401	81	16	fever	fever	NOUN
dti-1401	81	17	and	and	CCONJ
dti-1401	81	18	skin	skin	NOUN
dti-1401	81	19	rash	rash	NOUN
dti-1401	81	20	.	.	PUNCT